**Whole-Exome Sequencing Association Study Implicates Genetic Effects on Viral Oncogenesis and Tumor Microenvironment in Nasopharyngeal Carcinoma**

Yanni Zeng[1,2,3#], Chun-Ling Luo[1,4#], Guo-Wang Lin[5#], Fugui Li[6], Xiaomeng Bai[1,2,3], Josephine Mun-Yee Ko[7], Yang Liu[1,4], Shuai He[1,4], Jia-Xin Jiang[1,4], Enya Hui Wen ONG[8], Zheng Li[9], Ya-Qing Zhou[1,4], Yun-He Zhou[1,4], An-Yi Xu[1,4], Shu-Qiang Liu[1,4], Yun-Miao Guo[10], Jie-Rong Chen[11], Xi-Xi Cheng[1,4], Yu-Lu Cao[1], Xia Yu[6], Biaohua Wu[6], Pan-Pan Wei[1,4], Zhao-Hui Ruan[1,4], Qiu-Yan Chen[1], Lin-Quan Tang[1], James D. McKay[12], Wei-Hua Jia[1], Hai-Qiang Mai[1], Jian-Jun Liu[13], Dong-Xin Lin[1], Chiea Chuen Khor[9], Melvin Lee Kiang CHUA[8,14,15*], Mingfang Ji[6*], Maria Li Lung[7*], Yi-Xin Zeng[1*], Jin-Xin Bei[1,4,16*†]

1. State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center - Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, P.R. China

2. Faculty of Forensic Medicine, Guangdong Province Translational Forensic Medicine Engineering Technology Research Center, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, P.R. China.

3. Guangdong Province Key Laboratory of Brain Function and Disease, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, P.R. China.

4. Department of Experimental Research, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.

5. Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, P.R. China.

6. Cancer Research Institute of Zhongshan City, Zhongshan City People 's Hospital, Zhongshan, P.R. China.

7. Department of Clinical Oncology, School of Clinical Medicine, University of Hong Kong, Hong Kong SAR, P.R. China.

8. Precision Radiotherapeutics Oncology Programme, Division of Medical Sciences, National Cancer Centre Singapore, Singapore.

9. Genome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.

10. Zhanjiang Institute of Clinical Medicine, Central People's Hospital of Zhanjiang,

Guangdong Medical University Zhanjiang Central Hospital, Zhanjiang, P. R. China.

11. Department of Laboratory Medicine, Guangdong Provincial People's Hospital (Guangdong

Academy of Medical Sciences), Southern Medical University, Guangzhou, P.R. China.

12. Genomic Epidemiology Branch, International Agency for Research on Cancer/World

Health Organization (IARC/WHO), France.

13. Laboratory of Human Genomics, Genome Institute of Singapore, Agency for Science,

Technology and Research (A*STAR), Singapore.

14. Department of Head and Neck and Thoracic Radiation Oncology, National Cancer Centre

Singapore, Singapore.

15. Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore.

16. Department of Medical Oncology, National Cancer Centre Singapore, Singapore.

# These authors contributed equally.

* Senior authors who jointly directed the study.

† Correspondence to:

Dr Jin-Xin Bei, State Key Laboratory of Oncology in South China, Sun Yat-sen University

Cancer Center, Guangzhou 510060, China

E-mail: beijx@sysucc.org.cn

## Abstract

Nasopharyngeal carcinoma (NPC) poses a substantial clinical challenge with limited understanding of its genetic underpinnings. Here we conduct the largest-scale whole-exome sequencing association study of NPC to date, involving 6,969 NPC cases and 7,100 controls and revealing three novel germline genetic variants linked to NPC susceptibility: a common variant rs2276868 in *RPL14*, a rare variant rs5361 in *SELE*, and a common variant rs1050462 in *HLA-B*. Through a multiomics approach, which integrates both bulk (n=206) and single-cell RNA-sequencing (n=56) data along with experimental validations, we demonstrate that the *RPL14* variant modulates Epstein-Barr virus (EBV) life cycle and NPC pathogenesis. Additionally, we show that the *SELE* variant plays a role in modifying endothelial cell function, thus promoting NPC progression. Our study also underscores the critical impact of rare genetic variants on NPC heritability. We introduce a refined composite polygenic risk score (rcPRS) that outperforms existing models in predicting NPC risk. Notably, our findings reveal that the polygenic risk for NPC is mediated by EBV infection status. Overall, our study provides crucial insights into the intricate genetic architecture of NPC. It highlights the critical interplay between genetic variations and essential elements of the tumor microenvironment, such as EBV and endothelial cells, in predisposing to NPC. This work opens new avenues for personalized risk assessments, early diagnosis, and targeted therapeutic strategies for NPC.

## Keywords

Nasopharyngeal carcinoma (NPC), whole-exome sequencing, genetic susceptibility, EBV, *RPL14, SELE,* HLA

**Highlights**

1. The largest whole-exome sequencing association study unveils three novel germline genetic variants linked to nasopharyngeal carcinoma (NPC) susceptibility, revealing the genetic architecture of NPC heritability with substantial contribution from rare variants.

2. *RPL14* variant modulates the Epstein-Barr virus life cycle and NPC pathogenesis, providing novel insights into genetic and viral interactions in cancer development.

3. *SELE* variant alters endothelial cell function and its favor to migration and metastasis of NPC, advancing our understanding of how genetic susceptibility variants influence tumor microenvironment components thereby contribute to cancer development.

4. A refined composite polygenic risk score (rcPRS) outperforms existing models in predicting NPC risk, emphasizing the influence of EBV infection status on NPC susceptibility.

## Introduction

Nasopharyngeal carcinoma (NPC) is a highly lethal malignancy that exhibits a significant geographic prevalence in specific regions of East and Southeast Asia[1]. These areas account for approximately 70% of new cases worldwide[1], with the highest incidence rate (9.69/100,000) reported in southern China area[2]. Familial clustering has been documented in a notable proportion (3.64~19%) of NPC patients from diverse populations[3-6], suggesting a strong link between family history and NPC risk[7]. Genetic susceptibility, Epstein-Barr virus (EBV) infection, and environmental effects are believed to play essential roles in NPC development[1].

Efforts have been made to identify germline variations contributing to the genetic susceptibility of NPC. Multiple linkage and association studies have reported that common genetic variants in HLA region confer a significant risk for NPC[8-11]. Besides the HLA loci, linkage studies have also identified risk loci in 4p12-p15, 3p21.31-21.2, and 5p13.1[9,12,13]. However, the replication of these linkage results has been challenging due to the diminishing size of family pedigrees and the low resolution of reported loci, limiting their practical application. Recently, genome-wide association studies (GWASs) have identified replicated common single nucleotide polymorphism (SNPs) in multiple loci associated with NPC risk, including *MECOM*, *CDKN2A/B*, *TNFRSF19*, *CIITA*, and *TERT/CLPTM1L*, in addition to the HLA loci[8,14-17]. However, these GWAS loci explain only a small portion (2.84%) of the overall NPC susceptibility[18], despite the relatively high heritability of NPC (10~61.3%)[19,20].

The issue of "missing heritability" (the gap between the heritability explained by GWAS loci and the total heritability) in NPC, similar to other complex polygenic diseases, may be attributed to the limited statistical power of studies targeting common variants (minor allele frequency (MAF)>=0.01) and even poorer power of studies capturing rare variants (MAF<0.01), such as those reported by utilizing whole-genome sequencing (WGS) or whole-exome sequencing (WES) [21,22]. Currently, only a few studies have examined the contribution of rare variants to NPC risk through WES, identifying NPC-associated genes such as *MST1R, RAD54L* and *POLN* [23-26]. However, these findings either did not reach exome-wide statistical significance or have not been independently validated, likely due to limited sample sizes or genetic heterogeneity across population. Therefore, the genetic architecture involving both common and rare variants in NPC risk remains unclear.

The role of EBV molecules in the screening and diagnosis of NPC is significant, as evidenced by their presence in NPC tumor and peripheral blood[27,28]. This is particularly

remarkable given that over 90% of the adult population is infected with EBV[29]. However, the

exact mechanisms linking EBV to NPC, and the potential involvement of host genetic

variations in those processes, are still enigmatic. EBV is known for its ability to transform B

cells into lymphoblastoid cell lines and for encoding oncogenic genes such as LMP1 and

BARFs[30]. In NPC, EBV infects epithelial cells and encodes viral genes related to NPC

progression[31]. Furthermore, the interaction of EBV with malignant epithelial cells and various

stromal cell types, each exhibiting unique gene expression profiles, fosters a complex tumor

microenvironment (TME), leading to both intra- and inter-tumor heterogeneity in NPC[32,33].

Despite these insights, the influence of genetic variations on TME components, and how this

contributes to NPC predisposition remains elusive.

This study aims to deepen our understanding of the genetic architecture of NPC and to

translate genetic findings into insights about its pathological mechanisms. We first conducted

a comprehensive two-stage association study, utilizing WES and capture-sequencing (Cap-seq)

analyses across multiple levels—variant, gene, and pathway—involving 14,069 individuals of

southern Chinese descent, including those from Guangdong, Hong Kong in China, and

Singapore. Furthermore, we employed extensive bulk and single cell RNA sequencing analyses,

along with experimental assays, to elucidate the functional mechanisms of the identified risk

loci. Critically, we uncovered the profound impact of both common and rare genetic variants

on cancer heritability, particularly how these genetic variations distinctly affect EBV-related

pathogenesis and TME components, thereby contributing to varying susceptibilities to NPC.

**Figure 1. Study overview.** A two-stage association study design was applied to investigate the genetic factors associated with NPC. In the discovery stage, a total of 5,022 samples, including the GD-SYSUCC cohort from Guangdong in China and the SG cohort from Singapore, were genotyped with WES and analyzed to identify four independent variants (two of which are novel), four novel genes, and 59 pathways associated with NPC. The associations were subsequently validated in the replication stage, which included 9,047 samples from the GD-ZS cohort in Guangdong and the HK cohort in Hong Kong, China. Bioinformatic analyses and functional experiments were conducted to explore the biological functions and the clinical implications of the novel loci.

## Results

### *Association of single variants with NPC susceptibility*

To identify susceptibility loci of NPC at single variant level, we first performed whole-exome sequencing (WES) on genomic DNA samples for the discovery stage, involving 2,694 NPC cases and 2,328 healthy controls of Han Chinese descent from southern China (GD-SYSUCC) and Singapore (SG; see Methods, **Figure 1**). After stringent quality controls, we obtained 1,043,522 single nucleotide variants (SNVs), including 362,993 potentially functional or pathogenic variants (Methods) and 335,163 novel variants which were not present in the 1000 genome phase 3, gnomAD exome, and genome database[34,35].

Subsequently, we performed a single-variant-based exome-wide association study (EWAS)

on 155,226 non-HLA SNVs and 1,783 HLA variants (including HLA alleles, amino acids [AA],

and SNVs) with a MAF $>=$ 0.001 among 2,694 NPC cases (all NPC cases, ALLNPC) and

2,328 controls, as well as 409 NPC cases with a family history (FHNPC) and the same set of

controls. We observed neither evidence of genomic inflation of the associations ($\lambda_{ALLNPC}$=1.07,

$\lambda_{FHNPC}$=0.89, **Figure S1A**) nor significant genetic substructure between case and control

groups (**Figure S2**). The EWAS results revealed a total of 242 variants associated with NPC

risk in the ALLNPC group and 128 variants associated with NPC risk in the FHNPC group,

surpassing the Bonferroni significant threshold for multiple testing correction ($P < 3.2 \times 10^{-7}$;

**Figure S1B**). Notably, we discovered a novel non-HLA locus with several significant

associated SNVs (**Figure S1B**). The sentinel SNV rs2276868, located at the 5'-untranslated

region (5'-UTR) of the ribosomal gene *RPL14*, exhibited the strongest associations in both the

FHNPC ($P_{FHNPC}$=$2.3 \times 10^{-8}$, Odds Ratio (OR) $_{FHNPC}$ =1.575, 95% Confident Interval (CI)

=1.343-1.846) and the ALLNPC groups ($P_{ALLNPC}$=$4.2 \times 10^{-7}$, $OR_{ALLNPC}$ =1.242, 95%CI=1.142-

1.351; **Table 1, Figure S1B**). Furthermore, the association was stronger in the family cases

than in the sporadic cases ($OR_{sporadic\_NPC}$ =1.200, 95%CI =1.097-1.313), indicating a robust

genetic predisposition to NPC. Conditional analysis revealed that all associations at the *RPL14*

locus vanished upon adjusting for rs2276868, suggesting that this variant explains all the

observed associations (**Table S1, S2**). Beyond the non-HLA locus, we also identified HLA

variants significantly associated with NPC (**Figure S1B**). Stepwise conditional analysis

localized three independently associated variants, including *HLA-DQB1\*03:01:01*, *HLA-A:*

*A_62_Q*, and rs1050462 at HLA-B (**Tables 1, Table S1**). Except for the two known

associations at *HLA-A: A_62_Q* and *HLA-DQB1\*03:01:01*[18,36], the association of rs1050462

with NPC is a novel discovery whose signal is not attributed to previously reported *HLA*

variants [8,10,11] (see Methods; $P \leq 3.23 \times 10^{-5}$; **Table S3**), according to an additional conditional

analysis using an extended GD-SYSUCC cohort consisting of 1,583 cases and 3,049 controls

with GWAS array data [17].

We next conducted validations of the identified associations using two independent

replication cohorts consisting of 9,047 samples of Southern Chinese recruited from Hong Kong

(HK; 2,334 cases and 2,507 controls) and Guangdong (GD-ZS; 1,941 cases and 2,265 controls)

in China (see Methods). We genotyped the samples using Cap-seq to target the genomic

regions spanning the above variants. Meta-analysis across the replication samples consistently

confirmed the associations of the four variants in *RPL14* and *HLA* loci ($P_{meta} < 0.05$; **Table 1**).

Moreover, when combining the discovery and replication samples, the meta-analysis revealed

that the four variants in *RPL14* and *HLA* loci were significantly associated with NPC risk,

surpassing the threshold for genome-wide significance ($P < 5 \times 10^{-8}$; **Table 1**).

***Association of genes and pathways with NPC susceptibility***

To identify the cumulative genetic effects of both rare and common variants within individual

genes on the risks of NPC, we conducted a gene-based association analysis in the discovery

dataset using an ensemble method that incorporates four algorithms simultaneously (see

Methods). For each gene, we performed separate tests that use all SNVs within the genic region

or only consider coding-affecting SNVs of that gene. Our analysis revealed a significant

association between *RPL14* and NPC, with statistical significance surpassing Bonferroni

threshold for multiple testing correction ($P < 2.3 \times 10^{-6}$, **Table 2**). Additionally, we validated

previous associations in several genes (**Table S4**).

We further performed a pathway-based analysis to explore the cumulative genetic effects

of genes involved in 6,204 curated molecular pathways in the discovery dataset (see Methods).

This analysis identified a total of 59 pathways associated with NPC in either the ALLNPC or

FHNPC groups, adhering to the false discovery rate (FDR) threshold set for multiple testing

correction ($P < 3.09 \times 10^{-4}$; **Figure 2A, Table S5)**. Among these pathways, we observed that

11 sentinel pathway genes were involved in at least two NPC-associated pathways and

exhibited an association with NPC in gene-based test with a significant threshold of $P < 0.01$

(**Figure 2B**). Notably, *SELE, NOTCH3*, and *FGFR3* had strong associations with NPC ($P <$

$1 \times 10^{-4}$; **Figure 2B**). *SELE* was particularly outstanding, with the strongest association with

NPC ($P_{SELE} = 2.69 \times 10^{-6}$) and the involvement in the largest number of NPC-associated

pathways (**Figure 2B**).

To validate the associations for the significant gene *RPL14* and the top three sentinel

pathways genes (*SELE*, *FGFR3*, and *NOTCH3*), we re-sequenced exon regions of these four

candidate genes in the replication cohorts ($n_{GD-ZS}$=4,206 and $n_{HK}$=4,841). Gene-based

association analyses statistically validated all the candidate genes in the replication dataset

($P_{RPL14}$=1.23 × 10^{-7}**, $P_{SELE}$=4.05 × 10^{-4}, $P_{NOTCH3}$=3.28 × 10^{-6}, and $P_{FGFR3}$=8.96 × 10^{-4}; **Table 2**).

The association for *RPL14* was particularly robust across all replication cohorts ($P_{GD-ZS}$=3.50

× 10^{-6} and $P_{HK}$=8.44 × 10^{-5}), whereas the associations for *SELE*, *NOTCH3*, and *FGFR3* were

more prominent in the GD-ZS cohort (**Table 2**).

**Table 1. Association of single variants with NPC susceptibility**

| Variant ID | CHR | A1 | Gene | ALLNPC: OR (95% CI) | P | FHNPC: OR (95% CI) | P | OR (95% CI) HK (2,334 cases and 2,507 controls) | OR (95% CI) GD-ZS (1,941 cases and 2,265 controls) | OR$_{meta}$: (95% CI) | P$_{meta}$ | I$_{meta}^2$ | OR$_{meta}$ (95% CI) | P$_{meta}$ | I$_{meta}^2$ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | **Discovery (2,694 cases and 2,328 controls)** | | | | **Replication (4,275 cases and 4,772 controls)** | | | | | **Combined samples (6,969 cases and 7,100 controls)** | | |
| rs2276868 | 3 | T | *RPL14* | 1.242 (1.142-1.351) | 4.16E-07 | 1.575 (1.343-1.846) | 2.30E-08 | 1.253 (1.154-1.36) | 1.193 (1.091-1.305) | 1.225 (1.153-1.302) | 5.26E-11 | 0.00 | 1.231 (1.172-1.293) | 1.22E-16 | 0.00 |
| DQB1*03:01:01 | 6 | Present | *HLA-DQB1* | 0.633 (0.568-0.705) | 1.00E-16 | 0.585 (0.467-0.734) | 3.64E-06 | 0.694 (0.622-0.774) | 0.589 (0.522-0.663) | 0.640 (0.545-0.752) | 5.56E-08 | 74.84 | 0.638 (0.582-0.700) | 9.43E-22 | 50.44 |
| A_62_Q | 6 | Present | *HLA-A* | 0.507 (0.462-0.556) | 4.61E-47 | 0.483 (0.401-0.581) | 1.20E-14 | 0.585 (0.532-0.642) | 0.560 (0.505-0.621) | 0.573 (0.535-0.615) | 1.73E-55 | 0.00 | 0.549 (0.504-0.598) | 4.69E-43 | 57.52 |
| rs1050462 | 6 | G | *HLA-B* | 0.646 (0.585-0.713) | 7.58E-18 | 0.637 (0.521-0.779) | 1.08E-05 | 0.568 (0.513-0.629) | 0.588 (0.526-0.658) | 0.577 (0.535-0.622) | 1.92E-46 | 0.00 | 0.600 (0.555-0.649) | 2.55E-37 | 40.86 |

Notes: CHR, chromosome; A1, target allele/amino acid; OR (95%CI), odds ratio estimate and the 95% confidence interval; I$^2$, the proportion of the variance in observed effect is due to variance in true effects rather than sampling error; Meta, meta-analyzed using the random effects model.

**Table 2. Associations of individual genes with NPC susceptibility**

| Gene Name | Significant in tests | SNV group | Method | P | P (GD-ZS; 1,941 cases and 2,265 controls) | P (HK; 2,334 cases and 2,507 controls) | P$_{meta}$ | Adjusted P$_{meta}$ | P$_{meta}$ |
|---|---|---|---|---|---|---|---|---|---|
| | | **Discovery (2,694 cases and 2,328 controls)** | | | **Replication (4,275 cases and 4,772 controls)** | | | | **Combined samples (6,969 cases and 7,100 controls)** |
| *RPL14* | Gene association | ALLSNV | SKAT (C+R) | 2.17E-06 | 3.50E-06 | 8.44E-05 | 1.23E-07 | 6.16E-07 | 1.79E-10 |
| *SELE* | Sentinel pathway genes | ALLSNV | SKAT (C+R) | 2.69E-06 | 1.01E-03 | 3.94E-02 | 4.05E-04 | 2.02E-03 | 1.44E-07 |
| *SELE* | Sentinel pathway genes | coding affecting SNV | SKAT (C+R) | 3.61E-06 | 1.36E-03 | 1.20E-01 | 1.40E-03 | 7.00E-03 | 4.63E-07 |
| *FGFR3* | Sentinel pathway genes | ALLSNV | Burden | 1.24E-04 | 7.40E-04 | 1.28E-01 | 8.96E-04 | 4.48E-03 | 3.64E-06 |
| *NOTCH3* | Sentinel pathway genes | ALLSNV | SKAT (C+R) | 3.60E-04 | 6.00E-06 | 1.07E-02 | 3.28E-06 | 1.64E-05 | 5.41E-08 |

Notes: ALLSNV, all SNVs; SKAT (C+R), SNP-set (Sequence) Kernel Association Test for the combined effect of common (C) and rare (R) variants; Burden, burden test; Meta, meta-analyzed using the summation of logits method; Adjusted P, the P value adjusted using the FDR method.

**Figure 2. Significant pathways and sentinel genes associated with NPC. A**. Significant
pathways associated with NPC. ALLNPC denotes all NPC samples in the discovery stage,
whereas FHNPC represents NPC cases with a familial NPC history. Color bars from white to
purple indicate minus log-transformed P values. **B**. Sentinel genes for NPC-associated
pathways. Genes indicated atop are highlighted in orange if they are part of a specific pathway.
The listed genes are those belonging to at least two NPC-associated pathways and exhibiting a
gene-based association P value below 0.01. **C**. Locations of the rare variants associated with
NPC at significance level of $P < 1×10^{-4}$ within the genic regions of SELE. Grey arrows denote
non-coding variants, blue arrows represent synonymous coding variants, and the red arrow
indicates non-synonymous coding variant predicted as "deleterious". The rs5361 minor allele
introduces a missense mutation at position 149, resulting in an amino acid substitution from S
to R. The index SNV rs3917410 showed the most significant P value in the association tests in
the discovery stage.

We next fine-mapped the variants (MAF > 0.001) contributing to the gene-level
associations for the four replicated genes using the discovery dataset (n=5,022). A constituent
variant was considered to have a "major" contribution if its variant-level association P value
was less than $1 × 10^{-4}$. Using this criterion, we detected a major contribution from a common
variant for *RPL14* (**Table S6**), as well as major contributions from multiple rare variants for
*SELE* (**Table S7**). However, no major contributing variants were detected for *FGFR3* (**Table
S8**) or *NOTCH3* (**Table S9**). Specifically, among the four SNVs (MAF > 0.001) in *RPL14*, the
sentinel SNV rs2276868 (MAF=0.36, $P_{SNV}$=4.16 × $10^{-7}$) and another SNV rs2276869
(MAF=0.10, $P_{SNV}$=0.001) shared modest linkage disequilibrium (LD; $R^2$=0.2) and were the

only two *RPL14* variants associated with NPC ($P_{SNV}$ <0.05; **Table S6**). Removing these two

SNVs from the gene-based analysis diminished the gene-level association of *RPL14* with NPC

($P_{gene}$=0.34). Controlling for rs2276868 also abolished the associations of rs2276869 (**Table**

**S6**). These findings suggest a predominant contribution of common variant rs2276868 to

*RPL14*'s association with NPC.

For *SELE*, a total of 23 SNVs (MAF > 0.001) were detected, including seven common

(MAF>=0.01) and 16 rare variants (MAF<0.01; **Table S7**). Of these, 10 SNVs were strongly

associated with NPC ($P_{SNV}$=2.68 × $10^{-5}$ ∼ 4.98 × $10^{-5}$; **Table S7**), with rs3917410 as the sentinel

SNV (P=2.68 × $10^{-5}$) and sharing nearly complete LD with the other nine SNVs ($R^2$ > 0.99;

**Table S7**). All the 10 SNVs are rare, including one non-synonymous coding (rs5361), three

synonymous coding, and six non-coding variants. Controlling for rs5361 variant abolished the

association signals with NPC for the other rare variants in *SELE* (Adjusted P>0.05; **Table S7**).

The rs5361 variant is a missense mutation (T>G) in the exon 4 of *SELE* (**Figure 2C**), resulting

in an amino acid substitution from the conservative Serine (S) (**Figure 2C, Figure S3A**) to

Arginine (R) at position 149. Furthermore, multiple algorithms predicted this S149R

substitution as "deleterious" (Polyphen-2 score=0.997; CADD score=23; SIFT score=0;

REVEL score=0.516; MetaLR score=0.772; **Figure S3B**). Collectively, these findings suggest

that the rare variant rs5361 (*SELE*-S149R) is likely a causal variant accounting for the NPC

associations observed in *SELE*.

*Functional characterization of the novel loci*

*Distinct cellular expression patterns of NPC-associated genes*

To understand the functional consequences of the novel loci in NPC, we first investigated their

cellular expression patterns along with the known NPC-associated genes (**Table S10**). We

harnessed single-cell transcriptomic analyses of tumor samples from 56 NPC patients and

various non-tumor tissues from 15 donors without cancer[37] (see Methods). *RPL14* exhibited a

universal expression across all cell types, notably in the malignant epithelial cells (**Figure 3**).

Similarly, most HLA-I genes also showed broad expression in all cell types. By contrast, *SELE*

exhibited specific expression in endothelial cells across both tumor and non-tumor tissues

(**Figure 3C, Figure S4**). We also noted specific expression of some genes in cell types other

than the malignant epithelial cells in NPC tumors (**Figure 3**). For example, *NOTCH3* was

specifically expressed in cancer associated fibroblasts, while HLA-II genes were mainly

expressed in various stromal cell types in the tumor microenvironment (TME; **Figure 3**).

Additionally, by performing single-cell transcriptomic analyses of tumor samples from other

epithelial cancers, including lung, gastric, and colorectal cancers (see Methods), we observed

that gene associated with those cancers exhibited similar expression patterns observed in NPC,

with some expressed predominantly in epithelial cells and some predominantly in stromal cells

in the TME (**Figure S5**). These findings strongly indicate that genes conferring susceptibility

to cancers are not necessarily confined to expression in malignant cells. Instead, these genes

often exhibit predominant expression in diverse cell populations within the TME, suggesting a

crucial role of genetic impact on stromal cells in cancer development.

**Figure 3. Expression patterns of novel and known NPC-associated genes across diverse cell types in NPC tumor tissues.** Single-cell transcriptomic analyses of 223,593 cells derived from NPC tumor tissues in 56 patients. **A**. UMAP plot of 223,593 single cells grouped into seven major cell clusters. **B**. Violin plot illustrating normalized expression of NPC-associated genes across these major cell clusters. All epithelial cells captured in NPC tumor were malignant (see Methods). **C**. The expression of the marker gene (*VWF*) for endothelial cells and alongside the novel NPC-associated gene *SELE*; top panel: initial UMAP plot, bottom panel: re-normalized UMAP emphasizing cells highlighted by the red circles in the initial UMAP plot.

### rs2276868 regulates RPL14 expression through the NKRF transcription factor

Given the location of rs2276868 at the RPL14 promoter [38] (**Figure S6, S7A**) and the stable expression of *RPL14* in malignant epithelial cells (**Figure 3**), we aimed to investigate the potential regulatory role of rs2276868 in *RPL14* mRNA expression in epithelial cells. We first performed a single-cell-transcriptome-based eQTL analysis using 15,623 malignant epithelial cells from tumor tissues of 35 NPC patients. We observed that CC or CT genotype of rs2276868 was significantly associated with a higher expression of *RPL14* in malignant NPC cells compared to the TT genotype (**Figure 4A**). Subsequently, luciferase reporter assay demonstrated that the rs2276868-[T] construct had significantly lower luciferase activity compared to the rs2276868-[C] construct in human 293T cells (**Figure 4B**). These findings strongly suggest the influence of rs2276868 on *RPL14* transcription, which may involve modulating the binding affinity of certain transcription factor (TF).

To identify such potential TF, we conducted a comprehensive screening and identified 24 candidate TFs, which showed a positive correlation with the mRNA expression of *RPL14* in two independent bulk transcriptomic datasets of NPC tissues ($n_{Bei}$=87 and $n_{Zhang}$=113; **Figure 4B, Figure S7B**). Subsequent siRNA screening assays confirmed that five of the 24 TFs were capable of modulating *RPL14* expression (**Figure S7C**). Among them, *NKRF* knockdown significantly reduced *RPL14* transcription in NPC cells (**Figure 4B, Figure S7C-E**). Furthermore, knockdown or overexpression of *NKRF* exhibited a preferential effect on the transcription activity of the rs2276868-[C] construct over the rs2276868-[T] construct in luciferase reporter assays (**Figure 4E, F**). Consistently, single-cell transcriptome analysis revealed a stronger positive correlation between the expression of *NKRF* and *RPL14* in malignant NPC cells carrying the rs2276868-[C] compared to the rs2276868-[T] carriers (**Figure 4J**). Moreover, chromatin immunoprecipitation (ChIP) assay demonstrated that NKRF specifically binds to a refined genomic region encompassing rs2276868 (**Figure 4G-I, S7F**). Taken together, these data strongly suggest that rs2276868 influences *RPL14* expression through its interaction with *NKRF*, which preferentially binds to the promoter region housing rs2276868-[C] to foster enhanced transcription of *RPL14* in NPC tumors.

**Figure 4. rs2276868 regulates the expression of *RPL14*. A**. Single-cell transcriptome analysis showed the mRNA expression of RPL14 in 15,623 malignant epithelial cells from 35 NPC samples with different rs2276868 genotypes. **B**. Relative luciferase activity changes in 293T cells transfected with plasmids containing rs2276868 -[C], -[T], or control vectors. **C**. Pearson correlation analysis indicates the relationship between *RPL14* and *NKRF* expression (measured as transcript per million, TPM) in transcriptome data of NPC patients (n=87). **D**. RT-qPCR illustrates the mRNA expression of RPL14 in NPC cells transfected with NKRF siRNAs or control siRNA. **E-F**. Relative luciferase activity in 293T cells co-transfected with the rs2276868 -[C] or -[T] plasmids and NKRF siRNA (F) or NKRF overexpression vectors (G). Corresponding statistics are presented at the right. **G**. Schematic diagram indicates primer pairs used for PCR amplification of RPL14 fragments. **H-I**. ChIP assay in S26 cells transfected with Flag-NKRF and control vectors. ChIP PCR (H) and qPCR (I) showed RPL14 expression level in cells. P1-3 denote primer pairs targeting genomic regions shown in G. **J**. Pearson correlation analysis indicates the relationship between NKRF and RPL14 expression in single-cell transcriptome data are different for NPC patients with different genotypes. rs2276868 -[CC/CT] patients have a stronger correlation than rs2276868-[TT] patients. *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$.

### *RPL14 suppresses EBV infection and lytic cycle in NPC*

To investigate the role of *RPL14* in NPC development, we first examined the relationship between *RPL14* expression and the transcriptional activity scores of various molecular pathways in NPC (see details in Methods). Through REACTOME and GO analysis of malignant epithelial cells in NPC scRNA-seq data ($n_{sample}$=35 and $n_{cell}$=15,623), we observed

a significant association between *RPL14* and a pathway related to viral translation
(GO:0019081: viral translation. $P_{sc}=1.63 \times 10^{-6}$; **Figure 5A, Table S11**). Additionally,
REACTOME and GO analysis of bulk RNA-seq data from NPC tissues ($n_{bulk\_Bei}$=93 and
$n_{bulk\_Zhang}$=113) revealed significant associations between *RPL14* and multiple pathways
related to viral infection. These pathways include SARS-COV-2 modulation of host translation
machinery ($P_{bulk\_Bei}=8.48 \times 10^{-16}$, $P_{bulk\_Zhang}=9.11 \times 10^{-14}$) and influenza infection
($P_{bulk\_Bei}=2.00 \times 10^{-14}$, $P_{bulk\_Zhang}=1.66 \times 10^{-13}$; **Figure S8; Table S12, S13**). Considering the
well-known involvement of EBV in NPC etiology[39], we hypothesized a potential link between
*RPL14* and EBV processes. Supportively, in EBV-positive malignant NPC cells, we observed
a significant negative association (R= -0.27, $P < 2.2 \times 10^{-16}$) between *RPL14* expression and the
EBV activity score, a metric developed by consolidating expression levels of multiple EBV
genes (see Methods; **Figure 5B**). Furthermore, rs2276868-[T] carriers exhibited decreased
*RPL14* expression but increased expression of EBV latent genes *LMP1* and *LMP2* as compared
to rs2276868-[C] carriers in the same cell group (**Figure 5C**). These results corroborate the
connection between *RPL14* and EBV-driven processes.

To further explore the interaction between *RPL14* and EBV, we monitored the protein
expression of RPL14 in NPC cells post EBV infection over different timepoints. We observed
a significant downtrend in RPL14 expression concurrent with EBV infection (**Figure 5D**). By
contrast, RPL14 knockdown resulted in a significant rise in EBV infection in NPC cells, while
RPL14 overexpression led to a marked reduction in EBV infection (**Figure 5E-H**).  We also
noticed a decline in RPL14 expression when EBV lytic cycle was induced using TPA and NaB
in NPC cells (**Figure 5I, J; Figure S9**). Furthermore, RPL14 knockdown remarkably
augmented the expression of EBV lytic genes in NPC cells, while RPL14 overexpression
significantly reduced their expression (**Figure 5K, L**). These observations strongly suggest that
RPL14 acts as a suppressor of EBV infection and lytic cycle in NPC.

**Figure 5. *RPL14* inhibits EBV infection and lytic cycle activation in NPC cells. A.** The top
20 pathways significantly associated with RPL14 expression in malignant epithelial cells from
NPC tumor. **B.** Correlation analysis between EBV-activity scores and *RPL14* expression within
malignant epithelial cells. **C.** Single-cell transcriptome analysis showing *LMP1* and *LMP2*
expression in NPC samples with either rs2276868 -[C] or -[T] genotypes. **D.** Western blot
examination of RPL14 and LMP1 protein levels in NPC cell lines S26 and HK-1 cells infected
with EBV at different timepoints. **E.** Western blot assessment of the knockdown efficiency of
RPL14 siRNAs or control siRNA in S26 and HK-1 cells. **F.** Flow cytometry quantification of
GFP intensity for the EBV infection efficiency in the NPC cells described in E. **G.** Western
blot assay showing RPL14 protein expression in S26 and HK-1 cells infected with lentivirus
stably expressing RPL14. ACTIN served as a loading control. **H**. Flow cytometry assessment
of EBV infection efficiency in the cells described in G. **I-J**. Changes of gene expression in
CNE2-EBV cells subjected to EBV lytic induction with TPA and NAB. RT-qPCR (I) and
western blotting (J) were performed to detect the mRNA and protein expression, respectively,
of RPL14 and EBV genes at different timepoints of EBV lytic induction. **K-L**. RT-qPCR
analysis of EBV lytic gene expression in CNE2-EBV and C666-1 cells transfected with RPL14
siRNAs or control siRNA (K), or infected with lentivirus stably expressing RPL14 vector or
control vector (L). \*$p < 0.05$, \*\*$p < 0.01$, \*\*\*$p < 0.001$, \*\*\*$p < 0.0001$.

### *RPL14 impedes tumorigenesis in NPC cells*

We next explored the function of *RPL14* in NPC tumorigenesis. We first manipulated *RPL14*
expression in an *in vitro* NPC cell model (**Figure 6A; S10A**). Cell growth curves and colony
formation assays revealed that the stable overexpression of *RPL14* significantly inhibited NPC
cell proliferation. Conversely, stable knockdown of *RPL14* had an opposite effect, promoting
proliferation (**Figure 6B-C, Figure S10B-C**). Transwell assays revealed that *RPL14*

overexpression suppressed NPC cell migration, while its knockdown enhanced the migration (**Figure 6D; Figure S10D**). These observations strongly suggest that *RPL14* inhibits the tumorigenesis of NPC cells.

**Figure 6. Tumor suppressive function of *RPL14* in NPC. A**. Western blot analysis showing RPL14 protein levels in NPC cells infected with RPL14 overexpressing lentivirus. ACTIN serves as the loading control. **B**. Cell growth curves of the cells described in A. **C**. Colony formation assay for the cells described in A. Corresponding statistical analysis is shown to the right. **D**. Transwell migration assay evaluating the migration ability of the cells described in A. The statistical analysis is presented on the right. **E-H**. Tumor growth evaluation in a nude mice model with subcutaneous injection of NPC cells described in A. Tumor volumes were measured every three days. Visual presentation of tumor post-sacrifice (F) and weight (G) were presented. IF detection of Ki-67 expression (H) in the tumors described in F, and the corresponding statistical analysis is shown on the right. **I**. Transcriptomic analysis showcasing mRNA levels of RPL14 in NPC (n=87) versus control samples (n=10). **J**. Kaplan-Meier survival analysis linking RPL14 expression to survival time in NPC patients using bulk RNA-seq data (n=88). *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$, ****$p < 0.0001$.

To corroborate the tumor-suppressive function of *RPL14 in vivo*, we established a mouse model with subcutaneous injection of NPC cells stably expressing *RPL14*. We observed a significant inhibition on tumorigenesis as reflected by the diminished tumor volume and weight in mice with *RPL14* overexpression compared to the control group (**Figure 6E-G**). Supportively, immunofluorescence staining of Ki-67, a proliferation marker, revealed a substantial decrease in Ki-67 positive cells in the *RPL14*-overexpressing tumors compared to

the control tumors (**Figure 6H**). Furthermore, we observed a significant lower expression of

*RPL14* in NPC tissues compared to nasopharyngeal tissues from individuals with rhinitis

(**Figure 6I**). Kaplan-Meier survival analysis revealed that low expression of *RPL14* was

significantly correlated with a poor prognosis of NPC patient (**Figure 6I**). These findings

strongly suggest *RPL14* as a tumor suppressor in NPC.

***SELE-S149R promotes NPC development through gain of function in endothelial cells***

*SELE* encodes E-selectin, a selectin cell adhesion molecule specifically expressed on the

surface of endothelial cells (**Figure 3C**). E-selectin plays a pivotal role in attracting cancer

cells by binding to ligands like glycoproteins[40]. Structural modeling of E-selectin paired with

glycomimetic antagonist ligand revealed that the Ser149 residue of SELE, implicated in the

rs5361 variant, is in close proximity to its ligand, and the S149R substitution (**Figure 2C**) leads

to an extension of E-selectin's side chain, potentially altering its interaction with glycoproteins

(**Figure 7A**). This aligns with a previous finding that *SELE*-S149R introduces a gain-of-

function effect on the recruiting capability of E-Selectin[41].

To probe the functional implications of the *SELE*-S149R mutation in the context of NPC,

we developed a model using human umbilical vein endothelial cells (HUVECs) stably

overexpressing either the wild-type SELE (*SELE*-Ser149, SELE-WT) or its S149R mutant

variant (SELE-MUT, **Figure 7B**). Transwell assays revealed that overexpression of SELE,

especially the SELE-MUT, significantly boosted the migration ability of HUVEC cells (**Figure**

**7C**). Tube formation assay further demonstrated that SELE, particularly the mutant form,

markedly enhanced the endothelial cell's ability to form capillary-like structures, (**Figure 7D**),

indicating a gain-of-function effect of the S149R mutation in promoting angiogenesis. We next

employed a co-culture model involving HUVECs (expressing either SELE-WT or MUT) and

NPC cell lines (HK-1 and S26). Strikingly, HUVECs overexpressing SELE, especially the

SELE-MUT variant, substantially increased the migration of NPC cells (**Figure 7E**). This was

further substantiated by *in vivo* xenograft assays, which showed increased tumorigenesis in

NPC cells co-cultured with HUVEC-SELE-MUT, evident from the augmented tumor volume

and weight (**Figure 7F-G**). Moreover, lymph node metastasis assays reinforced these findings,

demonstrating that co-culture with HUVEC-SELE-MUT cells substantially promoted the

metastasis of NPC cells (**Figure 7I-K**). These results strongly suggest that *SELE*-S149R

mutation in endothelial cells plays a crucial role in escalating both tumorigenesis and metastasis in NPC cells.

**Figure 7. SELE-S149R mutation in endothelial cells promotes the tumorigenesis and metastasis of NPC cells. A.** Structure prediction of E-selection paired with glycomimetic antagonist ligand 2-acetamido-2-deoxy-beta-D-glucopyranose (PDB code 4C16). The spatial proximity between Ser149 and the ligand is highlighted. Both the Ser149 side chain and the ligand are shown as sticks, with the distances between the OG atom of Ser149 and the C8 or O7 atoms of the ligand specified. **B.** Western blot examination of SELE protein level in HUVEC cells infected with lentivirus overexpressing SELE-WT, S149R mutant or control vectors. **C.** Transwell migration assay evaluating the migration ability of the cells described in A, with statistical analysis presented at the bottom. Scale bar, 100 μm. **D.** Tube formation assay with cells described in A. The statistical analysis is presented on the right. Scale bar, 100 μm. **E.** Transwell migration assay assessing the migration ability of the NPC cell lines (S26 and HK-1) co-cultured with HUVEC cells from A (S26/HK-1: HUVEC = 10:1), accompanied by statistical analysis presented at the bottom. Scale bar, 200 μm. **F-H.** Tumor growth evaluation in xenograft model with subcutaneous injection of S26 cells described in E. Tumor volumes. (F) are measured and visual presentation of tumor post-sacrifice (G) and weight (H)

520 are presented. **I-K.** Tumor lymphatic metastasis of S26 cells described in E. Lymph nodes are
521 visualized (I) and measured (J), with HE staining conducted to assess metastasis in these lymph
522 nodes (K). Scale bar, 100 μm. $*p < 0.05$, $**p < 0.01$, $***p < 0.001$.

### *Genetic contributions of common and rare variants to NPC susceptibility*

We next undertook a comprehensive analysis to quantify the overall heritability of NPC
explained by SNVs derived from WES, which was further broken down based on the MAF and
LD score classifications of these SNVs, using GREML-LDMS model (see Methods). We
observed that a total of 15.2% of NPC susceptibility (with a standard error of 3.6%) could be
explained by the genetic effects of all WES-derived SNVs, including 4.4% and 10.8%
attributed to variants within the HLA and non-HLA regions, respectively. Notably, rare
variants (MAF < 0.01) in the non-HLA regions explained a substantial 82.4% of the WES
SNV-heritability (**Figure 8A**). Furthermore, variants with the lowest LD scores, meaning
relative independence, contributed the largest proportion (30.6%) to the WES SNV-heritability
(**Figure 8A**).

Through a comparative analysis using a joint model that considers multiple genetic risk
factors simultaneously (see Methods), we further revealed that the minor allele G of the rare
variant *SELE*-rs5361 conferred a substantial disease risk (OR=2.20~2.22, **Figure S11**) in the
two Guangdong cohorts (GD-SYSUCC and GD-ZS). This risk level is comparable to that
associated with the highest 20% of the population's polygenic risk score (PRS) derived from
HLA variants (OR=2.14~2.30, **Figure S11**). Intriguingly, the risk also overshadowed that
conferred by the minor allele T of the common variant *RPL14*-rs2276868 (OR = 1.22~1.45) or
the highest 20% of the population's PRS for NPC from non-HLA GWAS variants (OR = 1.31-
1.80, **Figure S11**). Additionally, by assessing the phenotypic variance ascribed to each locus[42],
we also revealed that HLA loci are predominantly responsible for the NPC phenotypic variance,
while the *RPL14* common variant significantly explain a greater portion of disease variance
than the *SELE* rare variant (**Figure S11**).

### *Polygenic risk prediction improved by novel loci and mediated by EBV infection*

To assess the efficacy of the novel loci in predicting NPC risk, we developed a refined
composite polygenic risk score (rcPRS) that simultaneously considers NPC-associated SNVs
and the leading SNVs in NPC-associated genes and pathways identified in our study and
previous GWASs (see Methods; **Table S15**). Notably, the rsPRS demonstrated a consistent

right-skewed distribution for NPC cases compared to controls across all discovery and
replication datasets (**Figure 8B**), suggesting a higher predictive value of rsPRS in identifying
individuals at risk. Furthermore, the rcPRS achieved an area under curve (AUC) for risk
prediction ranging between 0.659 and 0.666 in the GD-SYSUCC discovery and replication
samples, outperforming the published GWAS-based PRS in the GD-SYSUCC sample (gPRS;
AUC = 0.649; **Figure 8C; see Methods**)[10]. This improvement in predictive accuracy is largely
attributable to the inclusion of two novel common variants, rs1050462 in *HLA-B* and
rs2276868 in *RPL14*, as evidenced by our leave-one-out analysis (**Table S16**). Further
stratification of individuals based on their NPC PRSs, either rcPRSs or gPRSs, revealed a more
pronounced rising trend in the relative disease risk with the escalating rcPRS compared to the
gPRS (**Figure 8D**). Individuals in the highest percentile rage (95-100%) of the rcPRS exhibited
approximately double the relative risk ($OR_{rcPRS\_discov}$=15.1) than those with the gPRS
($OR_{gPRS\_discov}$=8.4; **Figure 8D**). These findings suggest that incorporating novel loci into the
rcPRS not only improves its accuracy in distinguishing disease risk but also enhances its
capability to stratify individuals based on their likelihood to develop NPC.

Noteworthily, in a subset of 1,018 cases and 774 controls from the GD-SYSUCC cohort
that had data on serological antibody against the EBV-encoded virus capsule antigen (EBV
VCA-IgA), we observed a stronger association between rcPRS and NPC susceptibility in
individuals tested seropositive for EBV VCA-IgA compared to those tested seronegative
**(Figure 8E)**. Interaction analysis statistically further confirmed that the association between
the rcPRS and NPC disease status was significantly mediated by EBV status ($P_{interaction}$=0.03).
These findings suggest that the polygenic risk of NPC is mediated by serum EBV activity, and
that rcPRS may have a greater utility in predicting NPC risk among individuals with serological
evidence of EBV infection.

**Figure 8. Contribution of common and rare variants to NPC susceptibility. A**. Fractional representation of NPC heritability attributable to non-HLA WES-SNVs, categorized by minor allele frequency (MAF) and linkage disequilibrium (LD). For each variant, MAF was calculated using the discovery samples, and LD score represented the aggregated $R^2$ with adjacent variants spanning a 200kb window. **B**. Density plots illustrating the PRS incorporating the novel loci and previously known GWAS loci (refined composite PRS, rcPRS) for cases and controls in both the discovery and replication cohorts. **C**. Receiver operating characteristic curves comparing the rcPRS and previously reported GWAS PRS (gPRS) for NPC across different cohorts. **D**. Relative odds ratio comparing the rcPRS or gPRS bins and the 5% lowest quantile group in different cohorts. **E**. Correlation of rcPRS with disease status in individuals categorized by their EBV VCA-IgA status.

**Discussion**

Here we conducted the largest whole-exome sequencing association study on NPC to date and unveiled three novel variants linked to NPC susceptibility, including the common variant rs2276868 in the promoter (5'-UTR) region of *RPL14*, the rare coding variant rs5361 in *SELE*, and another common variant rs1050462 in HLA-B locus[8,11]. Notably, the identification of the *RPL14* locus underscores the significant role of familial history in NPC. This mirrors patterns observed in other complex diseases[42], suggesting both genetic or environmental factors related to family history might amplify the genetic impact of individual variants on NPC risk. A possible explanation for this locus remaining undetected earlier could be its pronounced genetic risk in familial cases ($OR_{FHNPC}$ =1.575) compared to sporadic cases ($OR_{sporadic\_NPC}$ = 1.200), coupled with the vast sample size of our study. Additionally, the successful replication of associations with *SELE* and other two sentinel pathway genes underlines an efficient approach to identify and decompose disease associations at the pathway level.

Our study sheds light on the functional roles of the novel genes, offering a better understanding of the pathogenic mechanisms underlying NPC. We uncovered that the variant rs2276868 modulates *RPL14* expression through the transcription factor *NKRF*, which is an inhibitor to the NF-κB pathway involved in NPC development[43,44]. Single-cell transcriptomic analyses revealed an inverse association between *RPL14* expression and EBV activity in malignant NPC cells, which is further corroborated by the suppressive effect of RPL14 on EBV infection and lytic cycle in NPC cells. Given the involvement of RPL22[45] and RPL4[46], both of which belong to the same RPL family as RPL14[47], in EBV infection, these findings highlight the crucial role of RPL family members in EBV life cycle. Furthermore, our study revealed that *RPL14* inhibits NPC tumorigenesis, consistent with its tumor-suppressive function reported in an *in vitro* NPC study[48] and in other cancer types[49]. Reinforcing this, a high *RPL14* expression is associated with a favorable survival of NPC. Taken together, our findings suggest that the polymorphism at rs2276868 predisposes individuals to varied *RPL14* expression, which in turn influences EBV-related tumorigenesis in NPC.

Besides *RPL14* in our study, multiple NPC-associated genes such as *HLA-I, -II*, and *CIITA* have been implicated in modulating EBV life cycle [29,30]. This reinforces that genetic variations affect EBV to mediate varied susceptibility to NPC. Significantly, our findings reveals that the effectiveness of the NPC polygenic risk score is influenced by the serological status of EBV activation. Given that both the EBV DNA load and antibodies against EBV are established serological markers for early NPC diagnosis[60,61], incorporating the rcPRS and EBV infection

markers could significantly enhance personalized risk assessments and lead to the development
of more effective screening strategies for NPC.

Our study has highlighted *SELE* as a novel NPC-associated gene. This association is likely
attributed to the rare germline mutation rs5361 in *SELE*, which encodes an adhesion protein E-
Selectin, known for its interactions with various cells, including leukocytes and malignant
epithelial cells[36,50]. A previous study has demonstrated that the deleterious S149R encoded by
rs5361 enhances the functionality of E-Selectin in endothelial cells, promoting their rolling and
adhesion capabilities[37]. Noteworthily, our study extends these findings by demonstrating that
*SELE* expression is confined to endothelial cells in tumor tissues. Our structural modelling and
functional experiments reveal that S149R mutation extends the SELE's side chain on the
surface of endothelial cells, thereby augmenting their migration and angiogenesis abilities.
Furthermore, we observed that endothelial cells expressing SELE, particularly those with the
S149R mutation, significantly render stronger migration and tumorigenesis to malignant NPC
cells. This supports the crucial role of E-selectin in interacting with cancer cells and modulating
metastasis across various cancers[36,51-53]. Therefore, these findings suggest that the *SELE-*
S149R may enhance the adhesion function of E-Selectin in endothelial cells, reshaping the key
TME component to favor the progression of cancer cells[53], consequently altering individual
susceptibility to NPC.

We further delved deeper into the cellular expression of various NPC-associated genes,
revealing versatile patterns. For example, certain genes, like *RPL14*, are expressed in most cell
types, including epithelial cells that give rise to malignant NPC cells. In contrast, genes like
*HLA-II* are found mainly in diverse stromal cells, which typically lack malignant potential in
NPC. Such patterns are also observed in other cancers. For instance, the well-known
susceptibility-associated genes *NOTCH4* in lung cancer and *SMAD1* in colorectal cancer[54,55]
are exclusively expressed in endothelial cells (not typically developing into malignancy) in
tumors. These findings highlight the multifaceted cellular implications of germline variations
in cancer susceptibility, resonating with a growing literature suggesting the engagement of
various cell types in the development of complex disease[56-58]. Given that the validation of the
functional relevance of genetic susceptibility genes often predominantly emphasizes the cells
of cancer origin (e.g., epithelial cells in NPC), our findings call attention to the importance of
exploring the roles of cancer risk genes across diverse TME cell types in cancer development
(such as endothelial cells)[54,55].

In summary, our study fills the missing heritability of NPC and enhances our
understanding of the genetic architecture of NPC by unveiling novel genetic associations from
variants of both common and rare prevalence. Furthermore, our study elucidates diverse
pathogenic mechanisms, including the EBV-mediated tumorigenesis in malignant epithelial
cells through *RPL14* and the adhesion component in endothelial cells via *SELE*. These findings
highlight the substantial impacts of genetic variants on EBV life cycle and various cell types
within the TME, which jointly contribute to NPC development. Moreover, our innovative
rcPRS model, incorporating these novel discoveries, reflects the modifier effect of EBV status
on polygenic risk and provides promising implications for NPC screening. Additionally, we
acknowledge limitations, including sample size constraints, especially for the FHNPC group
and rarer variants, and the need for further studies to delve into the mechanistic links between
these genetic variants and NPC pathogenesis. Future work should explore the potential clinical
benefits of these findings in NPC management.

## Acknowledgement

We acknowledge supports from the National Natural Science Foundation of China (NSFC;
82261160657, 81971270), the National Key R&D Program of China (NKRDPC;
2022YFC3400901 and 2021ZD0202000), the Sci-Tech Project Foundation of Guangzhou City
(201707020039), the Guangdong Innovative and Entrepreneurial Research Team Program
(2016ZT06S638), the Chang Jiang Scholars Program (J.X.B.), Hong Kong Research Grant
Council (RGC) Theme-based Research Scheme Funds (T12-703/22-R and T12-703/23-N),
National Medical Research Council Singapore Clinician Scientist Award
(NMRC/CSAINV20nov-0021), the Duke-NUS Oncology Academic Program Goh Foundation
Proton Research Programme (M.L.C), NCCS Cancer Fund (M.L.C), the Kua Hong Pak Head
and Neck Cancer Research Programme (M.L.C), the Research Grants Council Area of
Excellence (AoE) Hong Kong NPC Research (AoE/M-06/08), and the Hong Kong Cancer
Fund (M.L.L.). We thank all participants in the study, staffs at the biobank of SYSUCC for
sample preparation, staffs at the Tissue Bank for providing NPC blood samples and the patient
demographics of the HK cohort, Tan Kah Min's support for technical support and sample
processing in SG cohort, and staffs at the High-Throughput Analysis Platform (HTAP) of
SYSUCC for data generation and processing.

**Author contributions**

Designed the study: J.X.B, Y.X.Z; procured financial support: J.X.B, M.L.C, M.L.L, M.J; sample recruitment, preparation, and data collection: M.J, F.G.L, C.C.K, Z.L, M.L.L, J.M.K, M.L.C, E.H.O, Y.M.G, J.R.C, S.H, S.Q.L, X.X.C, X.Y, B.W, Y.H.Z, A.Y.X, P.P.W, Q.Y.C, L.Q.T, W.H.J, H.Q.M; analyzed and interpreted data: Y.Z, J.X.B, C.L.L, G.W.L, X.B, Y.L, S.H, Z.H.R, Y.L.C, C.C.K, J.J.L, M.L.C, J.M.K, E.H.O, J.D.M, D.X.L; performed functional experiments: C.L.L, J.X.J, Y.Q.Z; wrote the paper (original draft): Y.Z, C.L.L, J.X.B; all authors approved the final report.

**Availability of data and materials**

Key data were deposited in the Research Data Deposit public platform (RDD; http://www.researchdata.org.cn ).

**Declaration of interests**

The authors declare no competing interests.

**Materials and Methods**

**Ethics**

The study was approved by the Sun Yat-sen University Cancer Center (SYSUCC) Ethics Committee (reference no. SL-B2021-032-03), the SingHealth Institutional Review Board (IRB protocol no. 2019/2177), and the Institutional Review Board (IRB) of the University of Hong Kong. Informed consent was obtained from all participants.

**Patient recruitment and sample preparation**

***Discovery stage***

A total of 3,039 NPC patients of Chinese Han ancestry was recruited from Guangzhou in Guangdong province of China (GD-SYSUCC; n= 2,196) by SYSUCC and from Singapore (SG; n=843) by the National Cancer Center (Singapore, collected from 1987-2018). A total of 2,692 healthy individuals of Chinese Han ancestry was recruited as controls from local community in Guangdong (GD-SYSUCC; n=1,355) and from Singapore (SG; n =1,337) by

Genome Institute of Singapore (Singapore, details have been described previously[63]). All NPC
cases were histologically diagnosed. All healthy controls declared free of cancer through
questionnaires. After stringent quality control, the discovery dataset consisted of 2,694 NPC
cases (2,125 from GD-SYSUCC and 569 from SG) and 2,328 healthy controls (1,068 from
GD-SYSUCC and 1,260 from SG). Serum immunoglobulin A (IgA) antibodies to Epstein-Barr
virus (EBV) capsid antigen (IgA-VCA) were available for 1,646 NPC patients and 918 controls
in GD-SYSUCC subset. Individuals with IgA-VCA >=1:20 was categorized as EBV positive.

***Replication stage***

The replication dataset included two cohorts: a Zhongshan cohort (GD-ZS) consisting of 1,941
cases and 2,265 controls recruited from the Zhongshan city in the Guangdong province by
Zhongshan City People's Hospital, and a Hong Kong cohort (HK) consisting of 2,334 cases
and 2,507 controls recruited from Hong Kong by the University of Hong Kong. Specifically
for the HK cohort, NPC cases and controls were collected by the Tissue Bank established under
the Area of Excellence (AoE) program from five Hong Kong public hospitals including Queen
Mary Hospital (QMH), Queen Elizabeth Hospital (QEH), Tuen Mun Hospital (TMH), Pamela
Youde Nethersole Eastern Hospital (PYNEH), and Princess Margaret Hospital (PMH) from
2010 to 2017, details have been described previously[11]. NPC cases were confirmed by
histopathology and enrolled with routine staging procedures according to the American Joint
Committee on Cancer (AJCC) TNM system, physical examination, and imaging tests. The
control population was recruited from the Red Cross and hospital cancer-free individuals from
QMH, QEH, TMH, PYNEH, and PMH. We considered GD-ZS as a Guangdong indigenous
cohort that shared regional demographic features with the discovery GD-SYSUCC cohort
collected from the same province, whereas the HK cohort shared ancestral genetics with other
cohorts but was relatively demographically different.

***Bulk RNA-Seq samples***

Tumor biopsy samples from 93 NPC patients were collected for bulk RNA-seq (labelled as
"the Bei-lab collection"), 87 of which had prognosis data available. Additional bulk RNA-seq
data of tumor tissues from 113 independent NPC patients with prognosis data available were
collected from a published study (labelled as "the Zhang-lab collection")[64]. We further
collected nasopharynx samples from 10 cancer-free individuals with inflammations in

nasopharynx at SYSUCC, which were used as controls. Biopsies were collected before any

treatment and immersed in RNAlater.

***NPC samples for Single-cell RNA-seq***

Tumor biopsies of 10 NPC patients were collected for single cell RNA sequencing (scRNA-

seq) in our previous study[32]. Among them, eight had tumor epithelial cells successfully

captured. By extracting data from four additional studies[33,65-67], we further collected scRNA-

seq data of 46 NPC tumor samples, 27 of which captured tumor epithelial cells[33,65-67]. In total,

scRNA-seq datasets consisting of 56 samples (of which 35 have epithelial cells captured) were

used in downstream analyses.

**Data generation, quality control and annotation**

***Whole exome sequencing and variant calling***

Whole blood DNA sample was extracted from all participants in the discovery dataset for

whole exome sequencing. Library was constructed using one of the three products: Agilent

SureSelect Human All Exon V6+UTR kit, Agilent SureSelect Human All Exon V5+UTR kit,

and Roche SeqCap EZ Exome + UTR Target Enrichment Kit. This was followed by sequencing

using a paired-end 2 x 150 bp protocol on an Illumina HiSeq instrument. A custom optimized

version of Sentieon[68] was applied to preprocess sequencings reads, align reads to human

genome using GRCh37 (hg19) assembly as reference, and conduct single nucleotide variant

(SNV) calling using algorithms following the GATK best-practice pipeline[69,70]. After GATK's

VQSR quality control, hard filtering was applied to remove the variants with 1) Read depth

(DP) <10; 2) Allelic Balance (AB) > 0.8 or < 0.2 for heterozygous genotype; 3) Genotype

quality (GQ) < 30. For rare variants (minor allele frequency < 0.01), we applied additional

stringent quality control based on per-read mutation rate, allelic balance, and strand bias

(defined as proportion of allele called by reads from one strand over that by any of the two

strands). We used 1000 genome phase 1 high confident SNP set as golden set to establish

parameter threshold range where high liability variants can be called. This led to the following

filtering for rare variants: 1) refining alignment by removing any read with a mismatch distance

against the reference larger than 8 bp (any indel event counts for 1 bp) and re-apply hard

filtering as described above; 2) setting variant-sample elements with strand bias > 0.95 or <

0.05 for heterozygous genotype, or >0.97 or <0.03 for homozygous genotype to missing; 3)

setting variant-sample elements with allelic Balance (AB) > 0.75 or < 0.22 for heterozygous

genotype , or with allelic Balance (AB) < 0.95 and > 0.04 for homozygous genotype to missing.

***Additional quality control for association test***

For both common and rare variants, we further removed variants that are 1) with a missing

rate >= 0.02; 2) with a Hardy-Weinberg equilibrium P value <= 1 x $10^{-6}$ in healthy controls; 3)

with a significant differential missing rate between case vs controls (Bonferroni corrected); 4)

variants in super duplicates or low complexity regions. Samples were removed if they are 1)

with a missing rate > 0.05; 2) with autosomal heterozygosity deviation outside 3 standard

deviations of the mean; 3) genetic outliers through eye check or with any the of top four

principal component value located outside 6 standard deviations of the mean. These filtering

steps were performed using PLINK[71]. We also removed one of each related pair (remained

sample t<0.05) using GCTA[72].

***HLA genotyping***

High resolution WES-based HLA typing was performed on the bam files using HLAScan

(v2.1.3) with default parameters and implemented HLA database[73]. PCR amplification HLA

typing was also performed on 135 WES samples to cross-validate the WES-based typing

procedures. The concordance of the HLA genotypes was high (> 94%) at four-digit resolution

level for most HLA genes, except for HLA-DQA1 and -DPB1 with a relatively lower

concordance being observed (> 80%). The HLA amino acid (AA) polymorphism was obtained

using HLA AA alignments in IPD-IMGT database[74]. The genotypes of HLA SNPs were

inferred by the SNP2HLA software[75].

***Capture sequencing for targeted genomic regions***

DNA library preparation was performed as described in the NadPrep DNA Library Preparation

Kit (#1002222; Nanodigmbio, Nanjing, China) for the MGI sequencing platform on the

MGISP-960 automated workstation (MGI Tech Co., Ltd., Shenzhen, China), in accordance

with the manufacturers' instructions. Hybridization capture-based target enrichment was

performed as described in the NadPrep Hybrid Capture Reagents kit (#1005101; Nanodigmbio)

on the MGISP-100 automated workstation (MGI Tech Co., Ltd., Shenzhen, China), in

accordance with the manufacturers' instructions. The library distribution was analyzed by
Qsep100 (BiOptic Inc, New Taipei City, China) and quantified by Qubit dsDNA HS Assay Kit
(Invitrogen, Termo Fisher Scientifc Inc, Waltham, USA). Final libraries were sequenced on
MGI DNBSEQ-T7 (MGI Tech Co., Ltd., Shenzhen, China) using a pair-end of 150 bp.

***Whole transcriptomic sequencing***

For bulk RNA-seq, total RNA was extracted from tissue or cell line using Rneasy Mini Kit
(Qiagen), with ribosomal RNAs removed by Ribo-Zero Magnetic kit (Illumina). TruSeq RNA
Library Prep Kit (Illumina) was used to construct the library, followed by RNA sequencing.
RNA-seq was conducted with a pair-end of 150 bp protocol on an Illumina Hiseq X sequencer.
Bowtie was used to map post-Qced reads to human reference genome (hg19) and Htseq was
used to quantify reads counts[76,77]. Per-gene expression level was normalized using transcripts
per million (TPM).  scRNA-seq was performed following the manufacturers' instructions (10x
Genomics single-cell 5' sequencing and 3' sequencing kits). Details were described in previous
studies[32,33,65-67].

***Variant annotation***

ANNOVAR was used to annotate SNV with following categories[78]:
1)  SNPs in dbSNP150 database.
2) Variants in population genetics database: 1000 genome phase 3, exome and genome subset
of the Genome Aggregation Database (EXAC, gnomAD).
3) within genes in NCBI RefSeq Gene database.
4) within genes of pathways in curated canonical pathways, GO Ontology items and oncogenic
signature gene sets as downloaded from Molecular Signatures Database v6.2[79].
5) variants that have potential functional consequences as they ranked at top 5% of the rank
score of CADD (Combined Annotation Dependent Depletion), or DANN (deleterious
annotation of genetic variants using neural networks) or fitCons (fitness consequence score) [80-
82].
6) 'pathogenic' or 'likely pathogenic' variants as annotated in InterVar database (clinical
interpretation of missense variants)[83];

**Statistical analysis**

*Single-variant-based association test*

For variants in non-HLA region, SNVs with a MAF >= 0.001 were included in a logistic

regression in which NPC disease status was regressed on the genotype of individual SNV. For

variants in HLA region, four types of variants were included in analysis: SNVs, four-digits

HLA alleles, six-digits HLA alleles, and amino acids. For each variant, two tests were

performed for three binary phenotypes: all NPC cases (ALLNPC) vs controls, and NPC cases

with family history (FHNPC) vs controls, respectively. Other covariates in the model includes

top five genetic principal components and gender. Bonferroni method was applied in multiple

testing correction (N=157,024), with significance threshold P value of $3.2 \times 10^{-7}$.

*Conditional analysis for single-variant-based associations*

To test whether the single-variant association from target SNV was independent of the

associations of other SNVs, conditional analysis was performed by jointly fitting each of the

SNVs to be conditioned as covariate variable in the regression model.

*SNV-set-based association analysis 1: gene-based test*

The gene boundary was defined by the transcription start and end sites. These was no MAF-

based filtering for this analysis (singletons were also included). Apart from testing using all

SNVs (SNV type 1), we also performed test that only consider coding-affecting SNVs. For

each SNV type, we tested 4 algorithms that are available on the "SKAT" package in R:

1) The original SNP-set (Sequence) Kernel Association Test (SKAT)[84].

2) The original Burden test[85].

3) SKAT for the combined effect of common and rare variants using the sum test as

described previously[86].

4) Burden test for the combined effect of common and rare variants using the sum test as

described previously[86].

For each gene tested using each SNV type for each phenotype, the result from the algorithm

with the most significant P value was remained. Top ten genetic principal components and

gender were included in the model as covariates. Bonferroni method was applied in multiple

testing correction (N=22,228), with significance threshold P value of $2.3 \times 10^{-6}$.

*SNV-set-based association analysis 2: pathway-based test*

The pathway information was downloaded from Molecular Signature Database, including

curated canonical pathways, GO Ontology items and oncogenic signature gene sets[79]. After

annotating SNVs to the pathways, we performed pathway-level association analysis to test

cumulative effect from both rare and common variants within a pathway on NPC risk. To avoid

false positive results driven by very small or very large gene set, we excluded pathways with a

size larger than 200 genes or smaller than 5 genes. The same grouping and algorithms applied

in the gene-based test were also applied here. Multiple testing correction was performed using

the FDR method ($N_{pathway}$=6,204).

*Meta-analysis for single-variant-based and gene-based associations.*

890    The random effect model (REML) was applied to meta-analyze the association between

891    individual variants and NPC using the R package "metafor"[87]. The summation of logits

892    method[88] was applied to meta-analyze the association between individual genes and NPC using

893    the R package "metap"[89].

*Structural modelling of E-selectin*

896    The molecular structure of the E-selectin complexed with glycomimetic antagonist 2-

897    acetamido-2-deoxy-beta-D-glucopyranose (PDB code 4C16) was modelled as previously

898    described[90]. PyMOL with the Adaptive Poisson-Boltzmann Solver plugin was used in the

899    evaluation of the electrostatic surface and the visualization.

*Assessing cell-type specific gene expression of NPC and other cancer-associated genes using*

*scRNA-seq data of tumor and non-tumor tissues*

Susceptibility gene list of NPC, lung, colorectal and gastric cancers included those identified

in present study (for NPC only) and those collected from published GWAS studies **(Table S10)**.

Expression profiles were derived from multiple scRNA-seq datasets: the NPC tumor dataset

($n_{sample}$=56, $n_{cell}$= 223,593) as described in "NPC samples for Single-cell RNA-seq" section;
the lung cancer tumor dataset ($n_{sample}$=19, $n_{cell}$=90,477) downloaded from the GEO database
(GSE131907, GSE139555) and collected from a previous pan-cancer study[91]; the gastric
cancer tumor dataset ($n_{sample}$=9, $n_{cell}$=28,299) provided by a published study[92]; the colorectal
cancer tumor dataset ($n_{sample}$=37, $n_{cell}$=70,015) downloaded from the GEO database
(GSE132465, GSE144735 and GSE139555); and the non-cancer tissue dataset consisting of
483,152 cells (for computational consideration, 100,000 cells were randomly selected in
downstream analyses) from 10 tissues of 15 donors provided by a published study[37]. The
quantification of gene expression and determination of cell types were performed separately
for each dataset.

Specifically, for NPC data we first used DoubletFinder to detect doublets[93] by inspecting
abnormal clusters that simultaneously express two or more cell type markers. For each sample,
doublets were removed with the expected doublet rate of 0.05. Cells with $n_{Feature\_RNA} > 500$,
$n_{Count\_RNA} > 1,000$ and percent.mt < 25% were retained for downstream analyses. Expression
Matrix of all cells were converted to a Seurat object and managed by Seurat's pipeline[94]:
normalization with NormalizeData and ScaleData, batch effect correction with Harmony[95],
dimensionality reduction with RunUMAP, clustering with FindNeighbors (k.param = 30) and
FindClusters. Clusters were annotated by classic markers as following: NK cells (KLRF1), T
cells (CD3D), Plasma cells (MZB1), B cells (MS4A1), Myeloid cells (AIF1), Cancer
Associated Fibroblasts (COL1A1), Endothelial cells (VWF) and Epithelial cells (EPCAM).
Normalized expression of marker genes for each cell type in each tumor datasets were shown
in **Figure S12**.

Lung, gastric, colorectal cancer tissue datasets were merged and analyzed. We first used
Scrublet[96] to remove estimated doublets and SoupX[97] to remove cell-free mRNA
contamination. Cells with $n_{Feature\_RNA} > 500$, $n_{Count\_RNA} > 1000$ and percent.mt < 25% through
quality control were kept for downstream analysis. NormalizeData and ScaleData in Seurat
was used to normalize data[98]; FindVariableFeatures with $n_{feature} = 3000$ was used to select
hypervariable genes. We used Harmony to correct for batch effect caused by different patients[95],
and used RunUMAP with dims = 1:30 and FindClusters with resolution = 0.3 for dimension
reduction and clustering. The clusters were annotated by classic markers of major cell types.
Normalized expression of marker genes for each cell type in each tumor datasets were shown
in **Figure S12**.

For the non-cancer tissue dataset, cell clusters were determined by the original study[37].

*Inference of malignant status of epithelial cells in scRNA-seq data in NPC tumor tissues*

Malignant cells have substantially increased copy number variation (CNV), such as large-scale gain or deletions of chromatin. Therefore, we use inferCNV to identify malignant epithelial cell clusters[99]. Comparing with control normal epithelial cells downloaded from GEO database (GSE121600), all epithelial cell clusters identified in NPC scRNA-seq data in our study were considered malignant.

*Estimate of WES-SNV heritability for NPC*

GREML-LDMS (the LD and MAF stratified GREML) approach was applied to estimate the proportion of NPC risk that can be explained by WES SNVs [100]. In brief, when calculating the total WES SNV-heritability and the proportion explained by variants from HLA and non-HLA regions, SNVs were stratified into four groups based on MAF and regions: MAF $\geq$ 0.01 in HLA region, MAF<0.01 HLA region, MAF $\geq$ 0.01 in non-HLA region and MAF < 0.01 in non-HLA region; when further decomposing the WES SNV-heritability in non-HLA region, SNVs were stratified into 28 groups based on LD scores (four bins based on quartiles. LD score was calculated as the sum of $R^2$ with variants in a 200kb window) and MAF (7 bins: 0.0005 < MAF <= 0.001 ,0.001 < MAF <=0.01, 0.01 < MAF <=0.1, 0.1 < MAF <= 0.2, 0.2 < MAF <=0.3, 0.3 < MAF <=0.4, and 0.4 < MAF <=0.5). For each SNV group, genomic relationship matrix (GRM) was created. In each model (the four components and 28 components ones), GRMs from all groups were then simultaneously fitted in the GREML model for NPC, where the total NPC variation explained by all genetic components and the variation explained by individual genetic component as represented by each GRM can by estimated.

*Joint model for a comparative analysis to estimate the relative risks by RPL14, SELE, HLA, and non-HLA GWAS loci*

In discovery samples, a subset (1,382 cases and 912 controls) of the GD-SYSUCC cohort simultaneously have imputed GWAS array[17] and WES data available, allowing the comparisons of the relative disease risks conferred by the common variant rs2276868 in *RPL14* and the rare variant *rs5361* in SELE with the polygenic risk from the HLA and other known GWAS loci. In replication samples, the cap-seq designed to target at both published GWAS

loci and the candidate loci identified by the presented WES study also enabled this comparison.

In brief, for each cohort we applied a joint regression model that simultaneously accounts for

genetic effects from different variants: the effects from *RPL14* and *SELE* were presented by

the genotypes of rs2276868 (*RPL14*) and rs5361(*SELE*), respectively; the combined genetic

effects from published non-HLA GWAS loci and that from HLA loci were represented as two

polygenic risk scores (one for non-HLA GWAS loci and one for HLA loci) constructed using

odds ratios estimated from original publication or our single-variant analysis using discovery

cohorts (**Table S14**).

## *Construction and evaluation of polygenic risk scores (PRS) for NPC*

### *1. Construction of a refined composite PRS (rcPRS) for NPC risk*

The rcPRS was calculated for all individuals with non-missing genotypes in the discovery

sample (the subset of 1,382 cases and 912 controls with both GWAS array and WES data

available[17] in GD-SYSUCC cohort) and in all replication samples (the capture sequencing

allowed the genotyping for  constituent variants of combined PRS). The following SNVs were

used to create rcPRS to simultaneously account for genetic risk factors identified in our WES

analyses and published GWASs[8,17,101]:

1)  In WES data, significant variants in single-variant-based association test (including HLA

variants identified in conditional analysis).

2)  In WES data, leading variants in gene-based test if they:

a.  were in genes significant in SKAT-gene-based association test.

b.  reached $P<1\times10^{-4}$ in single-SNV-based association test.

3)  In WES data, leading variants in pathway-based test as they:

a.  were in a gene of significant pathways and that gene has a $P<0.01$ in gene-based test.

b.   reached $P<1\times10^{-4}$ in single-SNV-based association test.

4)  Published GWAS loci [8,17,101]. Only non-HLA GWAS loci was extracted from this source

as majority of HLA SNPs identified in published GWAS were in non-coding regions,

which are beyond the regions captured by WES and that signals from HLA regions have

already been included in source 1.

To avoid duplication due to overlapped genes among pathways, each variant can be used

only once. Clumping was performed so that in each cluster of LD partners with $R^2>=0.1$ (within

250kb extended windows) only one variant could be remained. PRS was created as the sum of

weighted genetic risk from all variants. For each variant, the weighted genetic risk was

calculated as the product of allele dosage and the coefficient of variant effect estimated in

single-variant-based test. For variants from published GWAS, the coefficient was extracted

from original publications [8,17,101]. Details of the constituent variants were shown in **Table S15**.

1006

### 2. Construction of GWAS-only PRS (gPRS) for NPC risk

For a subset sample (n=2, 294) of the discovery GD-SYSUCC cohort, we produced imputed

genotypes for BeadChips array data. In brief, SNP array data was obtained from a previous

study[8]. To prepare the data for imputation analysis, we first used Liftover to convert the SNP

array data from hg18 to hg19 encoding strand. Next, we performed quality control at the SNP

level, removing SNPs with a minor allele frequency (MAF) less than 0.01, genotype missing

rate greater than 0.05, and those that failed the Hardy-Weinberg equilibrium test (HWE) with

a P-value less than $10^{-5}$. A total of 463,270 SNPs passed quality control and were retained for

further analysis. For the quality-controlled genotype data, we used SHAPEIT2 with default

parameters to estimate haplotypes of the study samples[102]. We then used IMPUTE2 with

default parameters and the haplotype data from the 1000 Genomes Project to impute the

missing genotype of each individual's haplotype[103]. After imputation, we removed SNPs with

an INFO value less than 0.8 and set loci with genotype probability (GP) values less than 0.9 to

missing. Ultimately, we retained 6,095,964 SNPs for analysis. This allows the construction of

a previous published PRS using NPC-associated loci reported by GWAS[10], following the

instruction from the original study[10]. To note, for three SNPs (rs2106123, rs6475604,

rs9507124) not genotyped and not imputed in GD-SYSUCC, we used three surrogate SNPs in

complete LD ($R^2$=1 in Chinese Southern Han population in 1000 genome phase 3 dataset) with

them (rs6774494 for rs2106123, rs1412829 for rs6475604, and rs9510790 for rs9507124) in

the model.

1027

### Construction of composite scores for pathway and EBV activity

1029  We applied the AddModuleScore function in R package Seurat [98] to profile each pathway from

1030  the REACTOME and the GO Ontology database in each sample, where bulk RNA-seq or

1031  scRNA-seq data was available. Based on AddModuleScore, the pathway score is obtained by

1032  subtracting the average expression of the corresponding control gene set from the average

1033  expression of the target gene set. For samples with scRNA-seq, we took each patient as a

datapoint, meaning that the average expression of a given gene across all epithelial cells from the patient was treated as the expression of that gene for the patient. We additionally created composite scores for EBV activity. In brief, we downloaded the EBV gene list from the EBV reference sequence (Akata; https://github.com/flemingtonlab/public/tree/master/annotation) and mapped the scRNA-seq data of EBV-positive malignant epithelial cells onto them. We then used the annotated EBV gene data to construct an EBV-composite score for each NPC patient with scRNA-seq data derived from EBV-positive epithelial cells available, following the same steps as described above.

### *The correlation between the pathway composite scores and RPL14 expression*

Pearson correlations between *RPL14* expression and composite scores were tested using the cor.test function in R. Multiple testing correction was performed using the FDR method. The Pearson correlations of individual EBV genes and *RPL14* were shown in **Table S17.**

## Functional characterization of NPC-associated loci

### *Cell culture*

Human NPC cell lines S26, CNE2-EBV, and HONE1-EBV were kindly gifted by Professor Mu-Sheng Zeng at the SYSUCC. Human NPC cell lines HK-1 and C666-1 were kindly gifted by Professor KW Lo at the Chinese University of Hong Kong. Human embryonic kidney cell 293T cell was purchased from Cell Bank of Type Culture Collection of Chinese Academy of Sciences, Chinese Academy of Sciences. All above cells were cultivated in DMEM medium containing 10% fetal bovine serum (FBS, Gibco, NY, USA) and 1% penicillin–streptomycin solution (FBS, Gibco, NY, USA). Human umbilical vein endothelial cells (HUVECs) were isolated and cultured in ECM medium (ScienCell, CA, USA) supplemented with 15% FBS and 0.03 mg/mL of endothelial cell growth supplement (ECGS, ScienCell, CA, USA). All cells were cultured at 37℃ under a humidified atmosphere with 5% CO2. For all cell lines, mycoplasma was routinely determined using PCR with specific primers and no contamination was detected (**Table S18**).

### *Cell proliferation*

For cell growth curves, a total of $1\times10^5$ NPC cells was plated in a 12-well plate with three

replicates. The number of cells was measured by a cell counter with trypan blue staining on 24,

48 and 72h. For colony formation assays, NPC cells were seeded at a density of 3000 cells per

replicate into 6-well plate for 7-10 days. Then, colonies were fixed with 4% paraformaldehyde

for 30min at room temperature. After stained with crystal violet for 10min, cells were

photographed with the Bio-Rad ChemiDoc Touch (Hercules, CA, USA).

1070

### Cell migration

Transwell assay was performed as described previously[104]. Briefly, NPC cells in serum-free

medium were plated at a density of $6\times10^4$ cells into the transwell chamber (8 µm pores, Corning,

NY, USA), which then placed at 24-well plates containing 600 µL DMEM suppled with 10%

FBS. After 16-24h, cells on the membrane were fixed with 4% paraformaldehyde for 30min

and stained with trypan blue solution for 15min at room temperature. Then the cells were

imaged under a microscope.

1078

### Luciferase reporter assay

Luciferase reporter assay was performed as described previously[105]. Briefly, the promoter

region of RPL14 containing the rs2276868-C or -T was cloned into a luciferase reporter pGL3-

basic plasmid. Afterwards, 293T cells were co-transfected with 200 ng of pGL3-RPL14-C or

-T constructs and 10 ng of pRL (Renilla luciferase) plasmid together with respective siRNAs

or overexpression plasmids. After 48h, cells were harvested to measure the luciferase activity

through a Dual-Luciferase Assay Kit (Promega, USA) according to the manufacturer's

instructions.

1087

### Immunofluorescence staining (IF)

Paraffin slides of xenograft tumors were deparaffinized with xylene and rehydrated through a

gradient ethanol series. After microwave antigen retrieval in sodium citrate solution (pH 6),

slides were incubated in 0.3% hydrogen peroxide for 15 min at room temperature to quench

the endogenous peroxidase activity. Afterwards, the samples were incubated with the primary

anti-Ki-67 (AB_393778, BD Pharmingen™, USA) antibodies overnight at 4 °C. Next day,

Alexa Fluor-conjugated secondary antibody (Thermo Fisher Scientific, USA) was used for 1 h

at room temperature, followed by counterstaining with antifade mounting medium and 4′,6-

diamidino-2-phenylindole (DAPI) for 10 min. Images were then captured with a confocal laser

scanning microscope (Carl Zeiss, Microscope 880, Germany).

1098

*Manipulating gene expression using siRNA and lentivirus*

For transient knockdown of target genes, siRNAs specific against RPL14 or NKRF were

transfected into cells using Lipofectamine RNAiMAX (Invitrogen, USA) according to the

manufacturer's protocol. After 48-72 hours, cells were harvested to detect the knockdown

efficiency of target genes through RT-qPCR as described below. Full length cDNA of NKRF

was cloned into the pcDNA3.1 vectors. RPL14, SELE-WT and MUT were cloned into the

pCDH-puro lentiviral vectors. For lentivirus preparation, 293T cells were transfected with

above lentivirus plasmids or control vector using Lipofectamine 2000 (Invitrogen, USA)

according to the manufacture's procedures. Afterwards, the supernatant media containing

lentivirus were collected two times at 24 and 48h post-transfection to infect NPC cell lines,

following selection with puromycin (2 μg/mL) at least for one week.

1110

*RNA isolation, RT-qPCR and ChIP PCR*

Total RNA was isolated using Trizol reagent (Invitrogen, USA) following the manufacturer's

protocols. After determination of RNA concentration using a Nanodrop Spectrophotometer

(Thermo Fisher Scientific, USA), cDNA was synthesized using oligo (dT) primers and M-

MLV Reverse Transcriptase (Promega, USA) according to the manufacturer's procedures. RT-

qPCR was performed with SYBR Premix Ex Taq kit (Takara, Japan) on a LightCycler 96 (Bio-

rad, USA). GAPDH or 18S RNA was used as an internal control. The primer sequences are

shown in **Table S18**. For ChIP assay, S26 cells transfected with Flag-NKRF plasmids or

control vectors were grown in complete DMEM media to 80%–90% confluency. The media

were removed and replaced with media containing 1% formaldehyde and crosslinked for

10 min at 37°C, followed by SimpleChIP® Plus Enzymatic Chromatin IP Kit (Magnetic Beads;

CST, USA) according to the manufacturer's instructions. Afterwards, PCR or qPCR was

performed with specific detection primers following the standard procedures (**Table S18**).

1124

*EBV preparation and infection*

AKATA cells carrying EBV recombinant viruses were treated with 0.75 (v/v) of goat anti-

human immunoglobulin G IgG (H0111-6, Tianfun Xinqu Zhenglong Biochem, China) for 6h

at 37℃ to induce the viral productive cycle. Virus supernatants were harvested three days post-

induction, filtered through a 0.45 μm filter and concentrated at 20000g for 3h. Afterwards,

virus concentrate was added into NPC cells and concentrated at 2000g in 37℃ for 1h. Cell

supernatants were removed and replaced with normal media 6-8h post-infection. The infection

efficiency was measured using flow cytometry analysis of GFP-positive cells.

1133

***Western blotting***

NPC cells were lysed in ice-cold cell lysis buffer (CST, USA) containing 1X protease inhibitors

(Beyotime, China). Lysate was cleared by centrifugation at 14,000g for 10 min at 4°C and

boiled in 1X LDS loading buffer at 100°C for 10 min. Proteins were separated by SDS-PAGE

and transferred to 0.2 μm polyvinylidene difluoride (PVDF) membrane (Merck Millipore,

USA). Membranes were blocked with 5% bovine serum albumin (BSA; Sangon Biotech, China)

in tris-buffered saline and Tween 20 (TBST) at room temperature for 1h. Afterwards, the

membranes were incubated with target-specific antibodies in blocking buffer at 4°C overnight.

Next day, horseradish peroxidase–conjugated (HRP) secondary antibodies were used at room

temperature for 1h. Proteins were then detected with Fdbio-Dura ECL kit (Fdbio science, China)

and quantified by Bio-Rad ChemiDoc Touch (Hercules, USA). Primary antibodies were

commercially available, including RPL14 and LMP1 (ab181200 and ab78113, Abcam, USA),

SELE (20894-1-AP, Proteintech, China), Flag (F1804, Sigma-Aldrich, USA), BZLF1(sc53904,

Santa Cruz, USA) and ACTIN (AC004, Abclonal, China).

1148

***In vivo tumor xenograft***

Six-week-old male BALB/c nude mice (Beijing Vital River Laboratory Animal Technology,

China) were grown in the Specific Pathogen Free (SPF) environment. For subcutaneous

xenograft assay, $5 \times 10^6$ CNE2-EBV cells or $2 \times 10^6$ S26 cells co-culturing with HUVEC cells

(S26: HUVEC = 10:1) were suspended in 100μL ice-old PBS mixed with Matrigel (0.20 v/v,

Corning Incorporated, USA) and subcutaneously injected to the two flanks of the mice.

Macroscopic observation and tumor volume measurement using a caliper were performed

every 3 days. After 15 days, all mice were sacrificed, and tumor tissues were carefully dissected

and weighed. Tumor volume was calculated following the formula: tumor volume (mm3) =

length (mm) × (width (mm)) 2 /2. For tumor lymphatic metastasis assay, $1×10^6$ S26 cells co-

culturing with HUVEC cells (S26: HUVEC = 10:1) were injected into the foot pads of the node

mice. After one month, the lymph nodes were harvested, volumed and paraffin embedded

further HE staining. For animal studies *in vivo*, all experiments were performed in strict

accordance with the instructions approved by the Institutional Animal Care and Use Committee

of Sun Yat-sen University.

1164

***Tube formation assays***

For tube formation assays, HUVEC cells stably expressing SELE wild-type (SELE-WT), the

S149R mutant or control vectors were resuspended in the ECM medium. Then the cells were

seeded into 96-well plates pre-coated with growth-factor-reduced Matrigel (Corning

Incorporated, USA) and incubated at 37°C for 5 hours. The formation of capillary-like

structures was subsequently observed using a microscope. Quantitative analysis was conducted

by counting the number of tube networks formed across the entire field, serving as an indicator

of *in vitro* angiogenesis capability.

1173

**References**

1    Chen, Y.-P. *et al.* Nasopharyngeal carcinoma. *The Lancet* **394**, 64-80,
doi:10.1016/s0140-6736(19)30956-0 (2019).
2    Wei, K. R. *et al.* Nasopharyngeal carcinoma incidence and mortality in China, 2013.
*Chin J Cancer* **36**, 90, doi:10.1186/s40880-017-0257-9 (2017).
3    Cao, S. M., Simons, M. J. & Qian, C. N. The prevalence and prevention of
nasopharyngeal carcinoma in China. *Chin J Cancer* **30**, 114-119,
doi:10.5732/cjc.010.10377 (2011).
4    Chen, C. *et al.* Multiple risk factors of nasopharyngeal carcinoma: Epstein-Barr virus,
malarial infection, cigarette smoking and familial tendency. **10**, 547-553 (1990).
5    IRELAND, B., LANIER, A. P., KNUTSON, L., CLIFT, S. E. & HARPSTER, A. J. I.
j. o. e. Increased risk of cancer in siblings of Alaskan native patients with
nasopharyngeal carcinoma. **17**, 509-511 (1988).
6    Loh, K. S. *et al.* Familial nasopharyngeal carcinoma in a cohort of 200 patients. **132**,
82-85 (2006).
7    Liu, Z. *et al.* Quantification of familial risk of nasopharyngeal carcinoma in a high-
incidence area. **123**, 2716-2725 (2017).
8    Bei, J. X. *et al.* A genome-wide association study of nasopharyngeal carcinoma
identifies three new susceptibility loci. *Nature genetics* **42**, 599-603,
doi:10.1038/ng.601 (2010).
9    Lu, S.-j. *et al.* Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA
regions. *Nature* **346**, 470-471 (1990).
10   He, Y. Q. *et al.* A polygenic risk score for nasopharyngeal carcinoma shows potential
for risk stratification and personalized screening. *Nature communications* **13**, 1966,
doi:10.1038/s41467-022-29570-4 (2022).

11    Ning, L. *et al.* Nasopharyngeal carcinoma MHC region deep sequencing identifies
HLA and novel non-HLA TRIM31 and TRIM 39 loci.  **3**, 759 (2020).
12    Xiong, W. *et al.* A susceptibility locus at chromosome 3p21 linked to familial
nasopharyngeal carcinoma. **64**, 1972-1974 (2004).
13    Hu, L.-F. *et al.* A genome-wide scan suggests a susceptibility locus on 5p13 for
nasopharyngeal carcinoma. **16**, 343-349 (2008).
14    Fachiroh, J. *et al.* Tobacco consumption and genetic susceptibility to nasopharyngeal
carcinoma (NPC) in Thailand. *Cancer Causes & Control* **23**, 1995-2002,
doi:10.1007/s10552-012-0077-9 (2012).
15    Ng, C. C. *et al.* A genome-wide association study identifies ITGA9 conferring risk of
nasopharyngeal carcinoma. *Journal of human genetics* **54**, 392-397,
doi:10.1038/jhg.2009.49 (2009).
16    Bei, J.-X. *et al.* A GWAS meta-analysis and replication study identifies a novel locus
within CLPTM1L/TERT associated with nasopharyngeal carcinoma in individuals of
Chinese ancestry.  **25**, 188-192 (2016).
17    Cui, Q. *et al.* An extended genome-wide association study identifies novel
susceptibility loci for nasopharyngeal carcinoma. **25**, 3626-3634 (2016).
18    Wang, T. M. *et al.* Fine-mapping of HLA class I and class II genes identified two
independent novel variants associated with nasopharyngeal carcinoma susceptibility.
**7**, 6308-6316 (2018).
19    Dai, J. *et al.* Estimation of heritability for nine common cancers using data from
genome-wide association studies in Chinese population.  **140**, 329-336 (2017).
20    Huang, S. F. *et al.* Familial aggregation of nasopharyngeal carcinoma in Taiwan. *Oral*
*Oncol* **73**, 10-15, doi:10.1016/j.oraloncology.2017.07.020 (2017).
21    Manolio, T. A. *et al.* Finding the missing heritability of complex diseases. *Nature*
**461**, 747-753, doi:10.1038/nature08494 (2009).
22    Genin, E. Missing heritability of complex diseases: case solved? *Human genetics* **139**,
103-113, doi:10.1007/s00439-019-02034-4 (2020).
23    Dai, W. *et al.* Whole-exome sequencing identifies MST1R as a genetic susceptibility
gene in nasopharyngeal carcinoma. *Proceedings of the National Academy of Sciences*
**113**, 3317-3322, doi:10.1073/pnas.1523436113 (2016).
24    Yu, G. *et al.* Whole-Exome Sequencing of Nasopharyngeal Carcinoma Families
Reveals Novel Variants Potentially Involved in Nasopharyngeal Carcinoma. *Scientific*
*reports* **9**, doi:10.1038/s41598-019-46137-4 (2019).
25    Wang, T. M. *et al.* Whole-Exome Sequencing Study of Familial Nasopharyngeal
Carcinoma and Its Implication for Identifying High-Risk Individuals. *J Natl Cancer*
*Inst* **114**, 1689-1697, doi:10.1093/jnci/djac177 (2022).
26    Xiao, R. W. *et al.* Rare POLN mutations confer risk for familial nasopharyngeal
carcinoma through weakened Epstein-Barr virus lytic replication. *EBioMedicine* **84**,
104267, doi:10.1016/j.ebiom.2022.104267 (2022).
27    Chan, K. A. *et al.* Analysis of plasma Epstein–Barr virus DNA to screen for
nasopharyngeal cancer.  **377**, 513-522 (2017).
28    Li, T. *et al.* Anti–Epstein–Barr Virus BNLF2b for Mass Screening for
Nasopharyngeal Cancer.  **389**, 808-819 (2023).
29    Winter, J. R. *et al.* Predictors of Epstein-Barr virus serostatus in young people in
England.  **19**, 1-9 (2019).
30    Hatton, O. L., Harris-Arnold, A., Schaffert, S., Krams, S. M. & Martinez, O. M. J. I. r.
The interplay between Epstein–Barr virus and B lymphocytes: implications for
infection, immunity, and disease.  **58**, 268-276 (2014).

| 1248 | 31 | Su, Z. Y., Siak, P. Y., Leong, C.-O. & Cheah, S.-C. J. F. i. m. The role of Epstein– |
| 1249 | | Barr virus in nasopharyngeal carcinoma. **14**, 1116143 (2023). |
| 1250 | 32 | Liu, Y. *et al.* Tumour heterogeneity and intercellular networks of nasopharyngeal |
| 1251 | | carcinoma at single cell resolution. *Nature communications* **12**, 741, |
| 1252 | | doi:10.1038/s41467-021-21043-4 (2021). |
| 1253 | 33 | Chen, Y.-P. *et al.* Single-cell transcriptomics reveals regulators underlying immune |
| 1254 | | cell diversity and immune subtypes associated with prognosis in nasopharyngeal |
| 1255 | | carcinoma. **30**, 1024-1042 (2020). |
| 1256 | 34 | Altshuler, D. M. *et al.* A global reference for human genetic variation. *Nature* **526**, |
| 1257 | | 68-74, doi:10.1038/nature15393 (2015). |
| 1258 | 35 | Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation |
| 1259 | | in 141,456 humans. *Nature* **581**, 434-443, doi:10.1038/s41586-020-2308-7 (2020). |
| 1260 | 36 | Trinh, C. T. H. *et al.* LMP1-EBV Gene Deletion Mutations and HLA Genotypes of |
| 1261 | | Nasopharyngeal Cancer Patients in Vietnam. *Pathophysiology* **30**, 1-12, |
| 1262 | | doi:10.3390/pathophysiology30010001 (2023). |
| 1263 | 37 | Tabula Sapiens, C. *et al.* The Tabula Sapiens: A multiple-organ, single-cell |
| 1264 | | transcriptomic atlas of humans. *Science* **376**, eabl4896, doi:10.1126/science.abl4896 |
| 1265 | | (2022). |
| 1266 | 38 | Moore, J. E. *et al.* Expanded encyclopaedias of DNA elements in the human and |
| 1267 | | mouse genomes. **583**, 699-710 (2020). |
| 1268 | 39 | Tsao, S. W., Tsang, C. M. & Lo, K. W. Epstein-Barr virus infection and |
| 1269 | | nasopharyngeal carcinoma. *Philosophical transactions of the Royal Society of* |
| 1270 | | *London. Series B, Biological sciences* **372**, doi:10.1098/rstb.2016.0270 (2017). |
| 1271 | 40 | Yasmin-Karim, S., King, M. R., Messing, E. M. & Lee, Y.-F. J. O. E-selectin ligand-1 |
| 1272 | | controls circulating prostate cancer cell rolling/adhesion and metastasis. **5**, 12097 |
| 1273 | | (2014). |
| 1274 | 41 | Yoshida, M. *et al.* E-selectin polymorphism associated with myocardial infarction |
| 1275 | | causes enhanced leukocyte-endothelial interactions under flow conditions. **23**, 783- |
| 1276 | | 788 (2003). |
| 1277 | 42 | Dornbos, P. *et al.* A combined polygenic score of 21,293 rare and 22 common |
| 1278 | | variants improves diabetes diagnosis based on hemoglobin A1C levels. *Nature* |
| 1279 | | *genetics* **54**, 1609-1614, doi:10.1038/s41588-022-01200-1 (2022). |
| 1280 | 43 | Van Den Bogaert, A. *et al.* The DTNBP1 (dysbindin) gene contributes to |
| 1281 | | schizophrenia, depending on family history of the disease. **73**, 1438-1443 (2003). |
| 1282 | 44 | Coccia, M., Rossi, A., Riccio, A., Trotta, E. & Santoro, M. G. J. P. o. t. N. A. o. S. |
| 1283 | | Human NF-κB repressing factor acts as a stress-regulated switch for ribosomal RNA |
| 1284 | | processing and nucleolar homeostasis surveillance. **114**, 1045-1050 (2017). |
| 1285 | 45 | Yi, M. *et al.* Rediscovery of NF-kappaB signaling in nasopharyngeal carcinoma: How |
| 1286 | | genetic defects of NF-kappaB pathway interplay with EBV in driving oncogenesis? *J* |
| 1287 | | *Cell Physiol* **233**, 5537-5549, doi:10.1002/jcp.26410 (2018). |
| 1288 | 46 | Elia, A., Vyas, J., Laing, K. G. & Clemens, M. J. J. E. j. o. b. Ribosomal protein L22 |
| 1289 | | inhibits regulation of cellular activities by the Epstein-Barr virus small RNA EBER-1. |
| 1290 | | **271**, 1895-1905 (2004). |
| 1291 | 47 | Shen, C.-L. *et al.* Ribosome protein L4 is essential for Epstein–Barr virus nuclear |
| 1292 | | antigen 1 function. **113**, 2229-2234 (2016). |
| 1293 | 48 | Klinge, S., Voigts-Hoffmann, F., Leibundgut, M., Arpagaus, S. & Ban, N. J. S. |
| 1294 | | Crystal structure of the eukaryotic 60 S ribosomal subunit in complex with initiation |
| 1295 | | factor 6. **334**, 941-948 (2011). |

Zhang, Z., Zhang, Y., Qiu, Y., Mo, W. & Yang, Z. J. B. Human/eukaryotic ribosomal protein L14 (RPL14/eL14) overexpression represses proliferation, migration, invasion and EMT process in nasopharyngeal carcinoma. **12**, 2175-2186 (2021).

Huang, X.-P. *et al.* Alteration of RPL14 in squamous cell carcinomas and preneoplastic lesions of the esophagus. **366**, 161-168 (2006).

Telen, M. J. J. H. O. C. Cellular adhesion and the endothelium: E-selectin, L-selectin, and pan-selectin inhibitors. **28**, 341-354 (2014).

Köhler, S., Ullrich, S., Richter, U. & Schumacher, U. J. B. j. o. c. E-/P-selectins and colon carcinoma metastasis: first in vivo evidence for their crucial role in a clinically relevant model of spontaneous metastasis formation in the lung. **102**, 602-609 (2010).

Zen, K. *et al.* CD44v4 is a major E-selectin ligand that mediates breast cancer cell transendothelial migration. **3**, e1826 (2008).

Esposito, M. *et al.* Bone vascular niche E-selectin induces mesenchymal–epithelial transition and Wnt activation in cancer cells to promote bone metastasis. **21**, 627-639 (2019).

Zhang, B. *et al.* NOTCH4ΔL12_16 sensitizes lung adenocarcinomas to EGFR-TKIs through transcriptional down-regulation of HES1. **14**, 3183 (2023).

Zhou, J. *et al.* Long noncoding RNA MALAT1 sponging miR-26a-5p to modulate Smad1 contributes to colorectal cancer progression by regulating autophagy. *Carcinogenesis* **42**, 1370-1379, doi:10.1093/carcin/bgab069 (2021).

Sato, G. *et al.* Pan-cancer and cross-population genome-wide association studies dissect shared genetic backgrounds underlying carcinogenesis. **14**, 3671 (2023).

Ma, Y. *et al.* Integrating single-cell sequencing data with GWAS summary statistics reveals CD16+ monocytes and memory CD8+ T cells involved in severe COVID-19. **14**, 16 (2022).

Skene, N. G. *et al.* Genetic identification of brain cell types underlying schizophrenia. **50**, 825-833 (2018).

Witte, J. S., Visscher, P. M. & Wray, N. R. The contribution of genetic variants to disease depends on the ruler. *Nature reviews. Genetics*, doi:10.1038/nrg3786 (2014).

Li, Q. & Cohen, J. I. J. C. c. m. r. Epstein-Barr virus and the human leukocyte antigen complex. **6**, 175-181 (2019).

Su, C. *et al.* EBNA2 driven enhancer switching at the CIITA-DEXI locus suppresses HLA class II gene expression during EBV infection of B-lymphocytes. **17**, e1009834 (2021).

Li, Z. *et al.* Association of rare CYP39A1 variants with exfoliation syndrome involving the anterior chamber of the eye. **325**, 753-764 (2021).

Zhang, L. *et al.* Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based SubtypesGenomic Subtypes of Nasopharyngeal Carcinoma. **15**, 1722-1732 (2017).

Jin, S. *et al.* Single-cell transcriptomic analysis defines the interplay between tumor cells, viral infection, and the microenvironment in nasopharyngeal carcinoma. **30**, 950-965 (2020).

Zhao, J. *et al.* Single cell RNA-seq reveals the landscape of tumor and infiltrating immune cells in nasopharyngeal carcinoma. **477**, 131-143 (2020).

Gong, L. *et al.* Comprehensive single-cell sequencing reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of nasopharyngeal carcinoma. **12**, 1-18 (2021).

Aldana, R. & Freed, D. Data Processing and Germline Variant Calling with the Sentieon Pipeline. *Methods in molecular biology* **2493**, 1-19, doi:10.1007/978-1-0716-2293-3_1 (2022).

| 1346 | 69 | Kendig, K. I. *et al.* Sentieon DNASeq variant calling workflow demonstrates strong |
| 1347 | | computational performance and accuracy. **10** (2019). |
| 1348 | 70 | DePristo, M. A. *et al.* A framework for variation discovery and genotyping using |
| 1349 | | next-generation DNA sequencing data. **43**, 491 (2011). |
| 1350 | 71 | Purcell, S. *et al.* PLINK: A tool set for whole-genome association and population- |
| 1351 | | based linkage analyses. *American journal of human genetics* **81**, 559-575, doi:Doi |
| 1352 | | 10.1086/519795 (2007). |
| 1353 | 72 | Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome- |
| 1354 | | wide complex trait analysis. *American journal of human genetics* **88**, 76-82, |
| 1355 | | doi:10.1016/j.ajhg.2010.11.011 (2011). |
| 1356 | 73 | Ka, S. *et al.* HLAscan: genotyping of the HLA region using next-generation |
| 1357 | | sequencing data. **18**, 1-11 (2017). |
| 1358 | 74 | Robinson, J. *et al.* Ipd-imgt/hla database. **48**, D948-D955 (2020). |
| 1359 | 75 | Jia, X. *et al.* Imputing amino acid polymorphisms in human leukocyte antigens. **8**, |
| 1360 | | e64683 (2013). |
| 1361 | 76 | Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. J. G. b. Ultrafast and memory- |
| 1362 | | efficient alignment of short DNA sequences to the human genome. **10**, R25 (2009). |
| 1363 | 77 | Anders, S., Pyl, P. T. & Huber, W. J. B. HTSeq—a Python framework to work with |
| 1364 | | high-throughput sequencing data. **31**, 166-169 (2015). |
| 1365 | 78 | Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic |
| 1366 | | variants from high-throughput sequencing data. *Nucleic acids research* **38**, e164, |
| 1367 | | doi:10.1093/nar/gkq603 (2010). |
| 1368 | 79 | Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach for |
| 1369 | | interpreting genome-wide expression profiles. *Proceedings of the National Academy* |
| 1370 | | *of Sciences of the United States of America* **102**, 15545-15550, |
| 1371 | | doi:10.1073/pnas.0506580102 (2005). |
| 1372 | 80 | Quang, D., Chen, Y. & Xie, X. DANN: a deep learning approach for annotating the |
| 1373 | | pathogenicity of genetic variants. *Bioinformatics* **31**, 761-763, |
| 1374 | | doi:10.1093/bioinformatics/btu703 (2015). |
| 1375 | 81 | Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD: |
| 1376 | | predicting the deleteriousness of variants throughout the human genome. *Nucleic* |
| 1377 | | *acids research* **47**, D886-D894, doi:10.1093/nar/gky1016 (2019). |
| 1378 | 82 | Gulko, B., Hubisz, M. J., Gronau, I. & Siepel, A. A method for calculating |
| 1379 | | probabilities of fitness consequences for point mutations across the human genome. |
| 1380 | | *Nature genetics* **47**, 276-283, doi:10.1038/ng.3196 (2015). |
| 1381 | 83 | Li, Q. & Wang, K. InterVar: Clinical Interpretation of Genetic Variants by the 2015 |
| 1382 | | ACMG-AMP Guidelines. *American journal of human genetics* **100**, 267-280, |
| 1383 | | doi:10.1016/j.ajhg.2017.01.004 (2017). |
| 1384 | 84 | Wu, M. C. *et al.* Rare-variant association testing for sequencing data with the |
| 1385 | | sequence kernel association test. **89**, 82-93 (2011). |
| 1386 | 85 | Li, B. & Leal, S. M. J. T. A. J. o. H. G. Methods for detecting associations with rare |
| 1387 | | variants for common diseases: application to analysis of sequence data. **83**, 311-321 |
| 1388 | | (2008). |
| 1389 | 86 | Ionita-Laza, I., Lee, S., Makarov, V., Buxbaum, J. D. & Lin, X. J. T. A. J. o. H. G. |
| 1390 | | Sequence kernel association tests for the combined effect of rare and common |
| 1391 | | variants. **92**, 841-853 (2013). |
| 1392 | 87 | Viechtbauer, W. J. J. o. s. s. Conducting meta-analyses in R with the metafor package. |
| 1393 | | **36**, 1-48 (2010). |
| 1394 | 88 | Becker, B. J. J. T. h. o. r. s. Combining significance levels. 215-230 (1994). |
| 1395 | 89 | M, D. metap: meta-analysis of significance values. *R package version 1.8* (2022). |

90    Preston, R. C. *et al.* E-selectin ligand complexes adopt an extended high-affinity
conformation. *J Mol Cell Biol* **8**, 62-72, doi:10.1093/jmcb/mjv046 (2016).
91    Qian, J. *et al.* A pan-cancer blueprint of the heterogeneous tumor microenvironment
revealed by single-cell profiling. **30**, 745-762 (2020).
92    Zhang, M. *et al.* Dissecting transcriptional heterogeneity in primary gastric
adenocarcinoma by single cell RNA sequencing. **70**, 464-475 (2021).
93    McGinnis, C. S., Murrow, L. M. & Gartner, Z. J. J. C. s. DoubletFinder: doublet
detection in single-cell RNA sequencing data using artificial nearest neighbors. **8**,
329-337. e324 (2019).
94    Hao, Y. *et al.* Integrated analysis of multimodal single-cell data. **184**, 3573-3587.
e3529 (2021).
95    Korsunsky, I. *et al.* Fast, sensitive and accurate integration of single-cell data with
Harmony. **16**, 1289-1296 (2019).
96    Wolock, S. L., Lopez, R. & Klein, A. M. J. C. s. Scrublet: computational
identification of cell doublets in single-cell transcriptomic data. **8**, 281-291. e289
(2019).
97    Young, M. D. & Behjati, S. J. G. SoupX removes ambient RNA contamination from
droplet-based single-cell RNA sequencing data. **9**, giaa151 (2020).
98    Hao, Y. *et al.* Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573-3587
e3529, doi:10.1016/j.cell.2021.04.048 (2021).
99    Patel, A. P. *et al.* Single-cell RNA-seq highlights intratumoral heterogeneity in
primary glioblastoma. **344**, 1396-1401 (2014).
100   Yang, J. *et al.* Genetic variance estimation with imputed variants finds negligible
missing heritability for human height and body mass index. *Nature genetics* **47**, 1114-
1120, doi:10.1038/ng.3390 (2015).
101   Bei, J.-X. *et al.* A GWAS Meta-analysis and Replication Study Identifies a Novel
Locus within CLPTM1L/TERT Associated with Nasopharyngeal Carcinoma in
Individuals of Chinese AncestryNPC GWAS Follow-up Identifies CLPTM1L/TERT
Locus. **25**, 188-192 (2016).
102   Delaneau, O., Marchini, J. & Zagury, J.-F. J. N. m. A linear complexity phasing
method for thousands of genomes. **9**, 179-181 (2012).
103   Howie, B. N., Donnelly, P. & Marchini, J. J. P. g. A flexible and accurate genotype
imputation method for the next generation of genome-wide association studies. **5**,
e1000529 (2009).
104   Luo, C. L. *et al.* RBFOX2/GOLIM4 Splicing Axis Activates Vesicular Transport
Pathway to Promote Nasopharyngeal Carcinogenesis. *Adv Sci (Weinh)*, e2004852,
doi:10.1002/advs.202004852 (2021).
105   Xu, X. C. *et al.* RNA-binding motif protein RBM47 promotes tumorigenesis in
nasopharyngeal carcinoma through multiple pathways. *J Genet Genomics* **48**, 595-
605, doi:10.1016/j.jgg.2021.05.006 (2021).
1436

1437

1438

1439

1440

1441

1442

1443

 **Figure and table legends**

 **Figure 1. Study overview.** A two-stage association study design was applied to investigate the
genetic factors associated with NPC. In the discovery stage, a total of 5,022 samples, including
the GD-SYSUCC cohort from Guangdong in China and the SG cohort from Singapore, were
genotyped with WES and analyzed to identify four independent variants (two of which are
novel), four novel genes, and 59 pathways associated with NPC. The associations were
subsequently validated in the replication stage, which included 9,047 samples from the GD-ZS
cohort in Guangdong and the HK cohort in Hong Kong, China. Bioinformatic analyses and
functional experiments were conducted to explore the biological functions and the clinical
implications of the novel loci.

**Figure 2. Significant pathways and sentinel genes associated with NPC. A**. Significant
pathways associated with NPC. ALLNPC denotes all NPC samples in the discovery stage,
whereas FHNPC represents NPC cases with a familial NPC history. Color bars from white to
purple indicate minus log-transformed P values. **B**. Sentinel genes for NPC-associated
pathways. Genes indicated atop are highlighted in orange if they are part of a specific pathway.
The listed genes are those belonging to at least two NPC-associated pathways and exhibiting a
gene-based association P value below 0.01. **C**. Locations of the rare variants associated with
NPC at significance level of $P < 1 \times 10^{-4}$ within the genic regions of SELE. Grey arrows denote
non-coding variants, blue arrows represent synonymous coding variants, and the red arrow
indicates non-synonymous coding variant predicted as "deleterious". The rs5361 minor allele
introduces a missense mutation at position 149, resulting in an amino acid substitution from S
to R. The index SNV rs3917410 showed the most significant P value in the association tests in
the discovery stage.

**Figure 3. Expression patterns of novel and known NPC-associated genes across diverse
cell types in NPC tumor tissues.** Single-cell transcriptomic analyses of 223,593 cells derived
from NPC tumor tissues in 56 patients. **A**. UMAP plot of 223,593 single cells grouped into
seven major cell clusters. **B**. Violin plot illustrating normalized expression of NPC-associated
genes across these major cell clusters. All epithelial cells captured in NPC tumor were
malignant (see Methods). **C**. The expression of the marker gene (*VWF*) for endothelial cells
and alongside the novel NPC-associated gene *SELE*; top panel: initial UMAP plot, bottom

1476     panel: re-normalized UMAP emphasizing cells highlighted by the red circles in the initial

1477     UMAP plot.

1478

**Figure 4. rs2276868 regulates the expression of RPL14**. **A**. Single-cell transcriptome

analysis showed the mRNA expression of RPL14 in 15,623 malignant epithelial cells from 35

NPC samples with different rs2276868 genotypes. **B**. Relative luciferase activity changes in

293T cells transfected with plasmids containing rs2276868 -[C], -[T], or control vectors. **C**.

Pearson correlation analysis indicates the relationship between *RPL14* and *NKRF* expression

(measured as transcript per million, TPM) in transcriptome data of NPC patients (n=87). **D**.

RT-qPCR illustrates the mRNA expression of RPL14 in NPC cells transfected with NKRF

siRNAs or control siRNA. **E-F**. Relative luciferase activity in 293T cells co-transfected with

the rs2276868 -[C] or -[T] plasmids and NKRF siRNA (F) or NKRF overexpression vectors

(G). Corresponding statistics are presented at the right. **G**. Schematic diagram indicates primer

pairs used for PCR amplification of RPL14 fragments. **H-I**. ChIP assay in S26 cells transfected

with Flag-NKRF and control vectors. ChIP PCR (H) and qPCR (I) showed RPL14 expression

level in cells. P1-3 denote primer pairs targeting genomic regions shown in G. **J**. Pearson

correlation analysis indicates the relationship between NKRF and RPL14 expression in single-

cell transcriptome data are different for NPC patients with different genotypes. rs2276868 -

[CC/CT] patients have a stronger correlation than rs2276868-[TT] patients. *$p < 0.05$, **$p <$

$0.01$, ***$p < 0.001$.

1496

**Figure 5. *RPL14* inhibits EBV infection and lytic cycle activation in NPC cells. A.** The top

20 pathways significantly associated with RPL14 expression in malignant epithelial cells from

NPC tumor. **B.** Correlation analysis between EBV-activity scores and *RPL14* expression within

malignant epithelial cells. **C.** Single-cell transcriptome analysis showing *LMP1* and *LMP2*

expression in NPC samples with either rs2276868 -[C] or -[T] genotypes. **D.** Western blot

examination of RPL14 and LMP1 protein levels in NPC cell lines S26 and HK-1 cells infected

with EBV at different timepoints. **E.** Western blot assessment of the knockdown efficiency of

RPL14 siRNAs or control siRNA in S26 and HK-1 cells. **F.** Flow cytometry quantification of

GFP intensity for the EBV infection efficiency in the NPC cells described in E. **G.** Western

blot assay showing RPL14 protein expression in S26 and HK-1 cells infected with lentivirus

stably expressing RPL14. ACTIN served as a loading control. **H**. Flow cytometry assessment

of EBV infection efficiency in the cells described in G. **I-J**. Changes of gene expression in

CNE2-EBV cells subjected to EBV lytic induction with TPA and NAB. RT-qPCR (I) and
western blotting (J) were performed to detect the mRNA and protein expression, respectively,
of RPL14 and EBV genes at different timepoints of EBV lytic induction. **K-L**. RT-qPCR
analysis of EBV lytic gene expression in CNE2-EBV and C666-1 cells transfected with RPL14
siRNAs or control siRNA (K), or infected with lentivirus stably expressing RPL14 vector or
control vector (L). *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$, ***$p < 0.0001$.

1515

**Figure 6. Tumor suppressive function of *RPL14* in NPC. A**. Western blot analysis showing
RPL14 protein levels in NPC cells infected with RPL14 overexpressing lentivirus. ACTIN
serves as the loading control. **B**. Cell growth curves of the cells described in A. **C**. Colony
formation assay for the cells described in A. Corresponding statistical analysis is shown to the
right. **D**. Transwell migration assay evaluating the migration ability of the cells described in A.
The statistical analysis is presented on the right. **E-H**. Tumor growth evaluation in a nude mice
model with subcutaneous injection of NPC cells described in A. Tumor volumes were
measured every three days. Visual presentation of tumor post-sacrifice (F) and weight (G) were
presented. IF detection of Ki-67 expression (H) in the tumors described in F, and the
corresponding statistical analysis is shown on the right. **I**. Transcriptomic analysis showcasing
mRNA levels of RPL14 in NPC (n=87) versus control samples (n=10). **J**. Kaplan-Meier
survival analysis linking RPL14 expression to survival time in NPC patients using bulk RNA-
seq data (n=88). *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$, ****$p < 0.0001$.

1529

**Figure 7. *SELE*-S149R mutation in endothelial cells promotes the tumorigenesis and**
**metastasis of NPC cells. A.** Structure prediction of E-selection paired with glycomimetic
antagonist ligand 2-acetamido-2-deoxy-beta-D-glucopyranose (PDB code 4C16). The spatial
proximity between Ser149 and the ligand is highlighted. Both the Ser149 side chain and the
ligand are shown as sticks, with the distances between the OG atom of Ser149 and the C8 or
O7 atoms of the ligand specified. **B.** Western blot examination of SELE protein level in
HUVEC cells infected with lentivirus overexpressing SELE-WT, S149R mutant or control
vectors. **C.** Transwell migration assay evaluating the migration ability of the cells described in
A, with statistical analysis presented at the bottom. Scale bar, 100 μm. **D.** Tube formation
assay with cells described in A. The statistical analysis is presented on the right. Scale bar, 100
μm. **E.** Transwell migration assay assessing the migration ability of the NPC cell lines (S26
and HK-1) co-cultured with HUVEC cells from A (S26/HK-1: HUVEC = 10:1), accompanied

by statistical analysis presented at the bottom. Scale bar, 200 μm. **F-H.** Tumor growth

evaluation in xenograft model with subcutaneous injection of S26 cells described in E. Tumor

volumes. (F) are measured and visual presentation of tumor post-sacrifice (G) and weight (H)

are presented. **I-K.** Tumor lymphatic metastasis of S26 cells described in E. Lymph nodes are

visualized (I) and measured (J), with HE staining conducted to assess metastasis in these lymph

nodes (K). Scale bar, 100 μm. *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$.

1548

**Figure 8. Contribution of common and rare variants to NPC susceptibility. A**. Fractional

representation of NPC heritability attributable to non-HLA WES-SNVs, categorized by minor

allele frequency (MAF) and linkage disequilibrium (LD). For each variant, MAF was

calculated using the discovery samples, and LD score represented the aggregated $R^2$ with

adjacent variants spanning a 200kb window. **B**. Density plots illustrating the PRS incorporating

the novel loci and previously known GWAS loci (refined composite PRS, rcPRS) for cases

and controls in both the discovery and replication cohorts. **C**. Receiver operating characteristic

curves comparing the rcPRS and previously reported GWAS PRS (gPRS) for NPC across

different cohorts. **D**. Relative odds ratio comparing the rcPRS or gPRS bins and the 5% lowest

quantile group in different cohorts. **E**. Correlation of rcPRS with disease status in individuals

categorized by their EBV VCA-IgA status.

1560

1561   **Table 1. Association of single variants with NPC susceptibility.** Notes: CHR, chromosome;

1562   A1, effective allele/amino acid; OR (95%CI), odds ratio estimate and the 95% confidence

1563   interval; $I^2$, the proportion of the variance in observed effect is due to variance in true effects

1564   rather than sampling error; Meta, meta-analyzed using the random effects model.

1565

1566   **Table 2. Associations of individual genes with NPC susceptibility.** Notes: ALLSNV, all

1567   SNVs; SKAT (C+R), SNP-set (Sequence) Kernel Association Test for the combined effect of

1568   common (C) and rare (R) variants; Burden, burden test; Meta, meta-analyzed using the

1569   summation of logits method; Adjusted P, the P value adjusted using the FDR method.

1570